1
|
Matagawa T, Sasazawa Y, Agui K, Fujimaki M, Kawano S, Ogura A, Takao KI, Igarashi M, Simizu S. Antiproliferative activities through accelerating autophagic flux by basidalin and its analogs in human cancer cells. Bioorg Med Chem Lett 2024; 104:129713. [PMID: 38522588 DOI: 10.1016/j.bmcl.2024.129713] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2024] [Revised: 03/11/2024] [Accepted: 03/21/2024] [Indexed: 03/26/2024]
Abstract
Basidalin, isolated from the basidiomycete Leucoagaricus naucina, has previously demonstrated antibacterial and antitumor properties against murine cancer cells in vivo, but its effects on human cancer cells remain unknown. In this study, we found that basidalin possesses antiproliferative activity against human cancer cell lines. To elucidate the antiproliferative mechanism of basidalin, we focused on autophagy. Treatment with basidalin led to an increase in LC3-II expression level, and accelerated autophagic flux through an mTOR-independent pathway. Moreover, according to the structure-activity relationship analysis-including newly synthesized basidalin analogs-the formyl group, not the amino group, contributes to the antiproliferative activities of basidalin against human cancer cells. Additionally, the antiproliferative activity of basidalin analogs was strongly correlated with autophagy-inducing activity, indicating that basidalin exhibits antiproliferative activity through autophagy induction. These data suggest that basidalin, characterized by its ability to upregulate autophagic flux, emerges as a novel anticancer drug.
Collapse
Affiliation(s)
- Tomoe Matagawa
- Department of Applied Chemistry, Faculty of Science and Technology, Keio University, 223-8522, Japan
| | - Yukiko Sasazawa
- Department of Applied Chemistry, Faculty of Science and Technology, Keio University, 223-8522, Japan; Research Institute for Diseases of Old Age, Juntendo University Graduate School of Medicine, Tokyo 113-8421, Japan; Department of Neurology, Juntendo University, Faculty of Medicine, Tokyo 113-8421, Japan
| | - Koki Agui
- Department of Applied Chemistry, Faculty of Science and Technology, Keio University, 223-8522, Japan
| | - Motoki Fujimaki
- Department of Neurology, Institute of Medicine, University of Tsukuba, Ibaraki 305-8576, Japan
| | - Sayaka Kawano
- Department of Applied Chemistry, Faculty of Science and Technology, Keio University, 223-8522, Japan
| | - Akihiro Ogura
- Department of Applied Chemistry, Faculty of Science and Technology, Keio University, 223-8522, Japan
| | - Ken-Ichi Takao
- Department of Applied Chemistry, Faculty of Science and Technology, Keio University, 223-8522, Japan
| | | | - Siro Simizu
- Department of Applied Chemistry, Faculty of Science and Technology, Keio University, 223-8522, Japan.
| |
Collapse
|
2
|
Zhu Y, Fujimaki M, Snape L, Lopez A, Fleming A, Rubinsztein DC. Loss of WIPI4 in neurodegeneration causes autophagy-independent ferroptosis. Nat Cell Biol 2024; 26:542-551. [PMID: 38454050 PMCID: PMC11021183 DOI: 10.1038/s41556-024-01373-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2023] [Accepted: 01/29/2024] [Indexed: 03/09/2024]
Abstract
β-Propeller protein-associated neurodegeneration (BPAN) is a rare X-linked dominant disease, one of several conditions that manifest with neurodegeneration and brain iron accumulation. Mutations in the WD repeat domain 45 (WDR45) gene encoding WIPI4 lead to loss of function in BPAN but the cellular mechanisms of how these trigger pathology are unclear. The prevailing view in the literature is that BPAN is simply the consequence of autophagy deficiency given that WIPI4 functions in this degradation pathway. However, our data indicate that WIPI4 depletion causes ferroptosis-a type of cell death induced by lipid peroxidation-via an autophagy-independent mechanism, as demonstrated both in cell culture and in zebrafish. WIPI4 depletion increases ATG2A localization at endoplasmic reticulum-mitochondrial contact sites, which enhances phosphatidylserine import into mitochondria. This results in increased mitochondrial synthesis of phosphatidylethanolamine, a major lipid prone to peroxidation, thus enabling ferroptosis. This mechanism has minimal overlap with classical ferroptosis stimuli but provides insights into the causes of neurodegeneration in BPAN and may provide clues for therapeutic strategies.
Collapse
Affiliation(s)
- Ye Zhu
- Department of Medical Genetics, University of Cambridge, Cambridge Institute for Medical Research, Cambridge, UK
- UK Dementia Research Institute, University of Cambridge, Cambridge Institute for Medical Research, Cambridge, UK
| | - Motoki Fujimaki
- Department of Medical Genetics, University of Cambridge, Cambridge Institute for Medical Research, Cambridge, UK
- UK Dementia Research Institute, University of Cambridge, Cambridge Institute for Medical Research, Cambridge, UK
| | - Louisa Snape
- Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge, UK
| | - Ana Lopez
- Department of Medical Genetics, University of Cambridge, Cambridge Institute for Medical Research, Cambridge, UK
- UK Dementia Research Institute, University of Cambridge, Cambridge Institute for Medical Research, Cambridge, UK
- Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge, UK
| | - Angeleen Fleming
- Department of Medical Genetics, University of Cambridge, Cambridge Institute for Medical Research, Cambridge, UK
- UK Dementia Research Institute, University of Cambridge, Cambridge Institute for Medical Research, Cambridge, UK
- Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge, UK
| | - David C Rubinsztein
- Department of Medical Genetics, University of Cambridge, Cambridge Institute for Medical Research, Cambridge, UK.
- UK Dementia Research Institute, University of Cambridge, Cambridge Institute for Medical Research, Cambridge, UK.
| |
Collapse
|
3
|
Shimizu M, Fujimaki M, Igami E, Ishiguro Y, Noda K, Okuma Y, Hattori N. Subacute Progressive Hearing Loss and Lower Body Parkinsonism in Primary Sjögren's Syndrome. Intern Med 2024; 63:853-856. [PMID: 37495532 PMCID: PMC11009000 DOI: 10.2169/internalmedicine.2158-23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/17/2023] [Accepted: 06/14/2023] [Indexed: 07/28/2023] Open
Abstract
In primary Sjögren's syndrome, it is extremely rare to observe subacute progressive lower-body parkinsonism with severe sensory hearing loss responsive to corticosteroid therapy. Sjögren's syndrome can cause heterogeneous symptoms; therefore, its diagnosis and introduction of treatment are prone to be delayed, particularly in cases without sicca symptoms or seronegative cases, which are more likely to be seen in patients with neurological complications. This report may help clinicians identify atypical early neurological symptoms in primary Sjögren's syndrome.
Collapse
Affiliation(s)
- Mai Shimizu
- Department of Neurology, Juntendo University Shizuoka Hospital, Japan
- Department of Neurology, Juntendo University School of Medicine, Japan
| | - Motoki Fujimaki
- Department of Neurology, Juntendo University Shizuoka Hospital, Japan
| | - Eriko Igami
- Department of Neurology, Juntendo University Shizuoka Hospital, Japan
- Department of Neurology, Juntendo University School of Medicine, Japan
| | - Yuta Ishiguro
- Department of Neurology, Juntendo University Shizuoka Hospital, Japan
| | - Kazuyuki Noda
- Department of Neurology, Juntendo University Shizuoka Hospital, Japan
| | - Yasuyuki Okuma
- Department of Neurology, Juntendo University Shizuoka Hospital, Japan
| | - Nobutaka Hattori
- Department of Neurology, Juntendo University School of Medicine, Japan
| |
Collapse
|
4
|
Miyamoto K, Saiki S, Matsumoto H, Suzuki A, Yamashita Y, Iseki T, Ueno SI, Shiina K, Kataura T, Kamagata K, Imamichi Y, Sasazawa Y, Fujimaki M, Akamatsu W, Hattori N. Systemic Metabolic Alteration Dependent on the Thyroid-Liver Axis in Early PD. Ann Neurol 2023; 93:303-316. [PMID: 36128871 PMCID: PMC10092289 DOI: 10.1002/ana.26510] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2022] [Revised: 09/18/2022] [Accepted: 09/19/2022] [Indexed: 01/31/2023]
Abstract
OBJECTIVE Parkinson's disease (PD) is a common neurodegenerative disease characterized by initial involvement of the olfactory bulb/amygdala or autonomic nerves followed by nigral degeneration. Although autonomic innervation strictly regulates multiorgan systems, including endocrine functions, circulation, and digestion, how dysautonomia in PD affects systemic metabolism has not been identified. In this study, we tried to estimate the pathogenic linkage of PD by nuclear medicine techniques, trans-omic analysis of blood samples, and cultured cell experiments. METHODS Thyroid mediastinum ratio of 123 I-metaiodobenzylguanidine (MIBG) scintigraphy was measured in 1,158 patients with PD. Furthermore, serum exosome miRNA transcriptome analysis and plasma metabolome analysis followed by trans-omic analysis were performed in patients with de novo PD and age-matched healthy control persons. Additionally, thyroid hormone was administered to skeletal muscle and liver derived cells to evaluate the effect of hypothyroidism for these organs. RESULTS Sympathetic denervation of thyroid correlating with its cardiac denervation was confirmed in 1,158 patients with PD by MIBG scintigraphy. Among patients with drug-naïve PD, comprehensive metabolome analysis revealed decreased levels of thyroxine and insufficient fatty acid β-oxidation, which positively correlate with one another. Likewise, both plasma metabolome data and transcriptome data of circulating exosomal miRNAs, revealed specific enrichment of the peroxisome proliferator-activated receptor (PPARα) axis. Finally, association of thyroid hormone with PPARα-dependent β-oxidation regulation was confirmed by in vitro experiments. INTERPRETATION Our findings suggest that interorgan communications between the thyroid and liver are disorganized in the early stage of PD, which would be a sensitive diagnostic biomarker for PD. ANN NEUROL 2023;93:303-316.
Collapse
Affiliation(s)
- Kengo Miyamoto
- Department of Neurology, Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - Shinji Saiki
- Department of Neurology, Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - Hirotaka Matsumoto
- School of Information and Data Sciences, Nagasaki University, Nagasaki, Japan.,Laboratory for Bioinformatics Research, RIKEN Center for Biosystems Dynamics Research, Saitama, Japan
| | - Ayami Suzuki
- Department of Neurology, Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - Yuri Yamashita
- Department of Neurology, Juntendo University Graduate School of Medicine, Tokyo, Japan.,Aging Biology in Health and Disease, Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - Tatou Iseki
- Department of Neurology, Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - Shin-Ichi Ueno
- Department of Neurology, Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - Kenta Shiina
- Department of Neurology, Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - Tetsushi Kataura
- Department of Neurology, Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - Koji Kamagata
- Department of Radiology, Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - Yoko Imamichi
- Department of Neurology, Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - Yukiko Sasazawa
- Research Institute for Diseases of Old Age, Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - Motoki Fujimaki
- Department of Neurology, Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - Wado Akamatsu
- Center for Genomic and Regenerative Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - Nobutaka Hattori
- Department of Neurology, Juntendo University Graduate School of Medicine, Tokyo, Japan
| |
Collapse
|
5
|
Igami E, Fujimaki M, Shimizu M, Ishiguro Y, Kodama T, Okuma Y, Hattori N, Noda K. Reversible Pisa syndrome caused by chronic subdural hematoma in a patient with Parkinson’s disease: a case report. BMC Neurol 2022; 22:432. [PMCID: PMC9664706 DOI: 10.1186/s12883-022-02972-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2022] [Accepted: 11/08/2022] [Indexed: 11/16/2022] Open
Abstract
Abstract
Background
Pisa syndrome (PS), characterized by lateral trunk flexion, is quite common in patients with Parkinson’s disease (PD). Patients with PS are older and have a significantly longer disease duration, more severe motor phenotype, ongoing combined treatment with levodopa and dopamine agonists, and higher levodopa equivalent daily dose. We describe here, to the best of our knowledge, the first case of a woman with PD who developed acute-onset PS caused by chronic subdural hematoma (CSDH).
Case presentation
A 70-year-old woman developed acute-onset lateral flexion of her trunk to the left side while standing, and she was admitted to our hospital. One month before, she had a mild head trauma with loss of consciousness. At 65 years of age, she noticed difficulty with walking and clumsiness with her hands. She was diagnosed as having PD (Hoehn and Yahr stage 2) and levodopa was initiated. Her symptoms were markedly improved. At 67 years of age, she developed orthostatic hypotension and was treated sequentially with fluids, compression stockings, and midodrine. Urgently performed brain computed tomography (CT) showed a CSDH in the right hemisphere resulting in a marked compression of the hemisphere. After surgical evacuation, her PS disappeared. She has fully recovered to her preoperative level of function.
Conclusion
The present case provides a valuable insight, that is, the mesial frontal lobe and its connections from the posterior parietal cortex play crucial roles in maintaining the body schema and in the pathophysiology of PS. This case suggests that CSDH should be considered when clinicians examine acute-onset PS, even in patients with neurodegenerative disorders such as PD. Appropriate patient triage and timely neurosurgical intervention should be considered.
Collapse
|
6
|
Ohba S, Fujimaki M, Kojima M, Suzuki Y, Ikeda K, Matsumoto F. A novel procedure for transoral resection for retropharyngeal lymph node metastasis in head and neck cancer recurrence. Oral and Maxillofacial Surgery Cases 2022. [DOI: 10.1016/j.omsc.2022.100274] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
7
|
Uehara Y, Ueno SI, Amano-Takeshige H, Suzuki S, Imamichi Y, Fujimaki M, Ota N, Murase T, Inoue T, Saiki S, Hattori N. Non-invasive diagnostic tool for Parkinson's disease by sebum RNA profile with machine learning. Sci Rep 2021; 11:18550. [PMID: 34545158 PMCID: PMC8452747 DOI: 10.1038/s41598-021-98423-9] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2021] [Accepted: 09/02/2021] [Indexed: 12/15/2022] Open
Abstract
Parkinson's disease (PD) is a progressive neurodegenerative disease presenting with motor and non-motor symptoms, including skin disorders (seborrheic dermatitis, bullous pemphigoid, and rosacea), skin pathological changes (decreased nerve endings and alpha-synuclein deposition), and metabolic changes of sebum. Recently, a transcriptome method using RNA in skin surface lipids (SSL-RNAs) which can be obtained non-invasively with an oil-blotting film was reported as a novel analytic method of sebum. Here we report transcriptome analyses using SSL-RNAs and the potential of these expression profiles with machine learning as diagnostic biomarkers for PD in double cohorts (PD [n = 15, 50], controls [n = 15, 50]). Differential expression analysis between the patients with PD and healthy controls identified more than 100 differentially expressed genes in the two cohorts. In each cohort, several genes related to oxidative phosphorylation were upregulated, and gene ontology analysis using differentially expressed genes revealed functional processes associated with PD. Furthermore, machine learning using the expression information obtained from the SSL-RNAs was able to efficiently discriminate patients with PD from healthy controls, with an area under the receiver operating characteristic curve of 0.806. This non-invasive gene expression profile of SSL-RNAs may contribute to early PD diagnosis based on the neurodegeneration background.
Collapse
Affiliation(s)
- Yuya Uehara
- Biological Science Research, Kao Corporation, Tochigi, Japan
- Department of Dermatology and Allergology, Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - Shin-Ichi Ueno
- Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan
| | | | | | - Yoko Imamichi
- Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan
| | - Motoki Fujimaki
- Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan
| | - Noriyasu Ota
- Biological Science Research, Kao Corporation, Tochigi, Japan
| | | | - Takayoshi Inoue
- Biological Science Research, Kao Corporation, Tochigi, Japan.
| | - Shinji Saiki
- Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan.
| | - Nobutaka Hattori
- Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan.
| |
Collapse
|
8
|
Abstract
INTRODUCTION Huntington's disease (HD) is an incurable, autosomal dominant neurodegenerative disease caused by an abnormally long polyglutamine tract in the huntingtin protein. Because this mutation causes disease via gain-of-function, lowering huntingtin levels represents a rational therapeutic strategy. AREAS COVERED We searched MEDLINE, CENTRAL, and other trial databases, and relevant company and HD funding websites for press releases until April 2020 to review strategies for huntingtin lowering, including autophagy and PROTACs, which have been studied in preclinical models. We focussed our analyses on oligonucleotide (ASOs) and miRNA approaches, which have entered or are about to enter clinical trials. EXPERT OPINION ASO and mRNA approaches for lowering mutant huntingtin protein production and strategies for increasing mutant huntingtin clearance are attractive because they target the cause of disease. However, questions concerning the optimal mode of delivery and associated safety issues remain. It is unclear if the human CNS coverage with intrathecal or intraparenchymal delivery will be sufficient for efficacy. The extent that one must lower mutant huntingtin levels for it to be therapeutic is uncertain and the extent to which CNS lowering of wild-type huntingtin is safe is unclear. Polypharmacy may be an effective approach for ameliorating signs and symptoms and for preventing/delaying onset and progression.
Collapse
Affiliation(s)
- Roger A Barker
- Department of Clinical Neurosciences, John Van Geest Centre for Brain Repair, and MRC-WT Cambridge Stem Cell Institute, University of Cambridge , Cambridge, UK
| | - Motoki Fujimaki
- Department of Medical Genetics, Cambridge Institute for Medical Research , Cambridge, UK.,UK Dementia Research Institute , Cambridge, UK
| | - Priya Rogers
- Department of Clinical Neurosciences, John Van Geest Centre for Brain Repair, and MRC-WT Cambridge Stem Cell Institute, University of Cambridge , Cambridge, UK
| | - David C Rubinsztein
- Department of Medical Genetics, Cambridge Institute for Medical Research , Cambridge, UK.,UK Dementia Research Institute , Cambridge, UK
| |
Collapse
|
9
|
Stamatakou E, Wrobel L, Hill SM, Puri C, Son SM, Fujimaki M, Zhu Y, Siddiqi F, Fernandez-Estevez M, Manni MM, Park SJ, Villeneuve J, Rubinsztein DC. Erratum: Author Correction: Mendelian neurodegenerative disease genes involved in autophagy. Cell Discov 2020; 6:40. [PMID: 32566248 PMCID: PMC7296028 DOI: 10.1038/s41421-020-0185-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Affiliation(s)
- Eleanna Stamatakou
- Department of Medical Genetics, Cambridge Institute for Medical Research, Cambridge, CB2 0XY UK.,UK Dementia Research Institute, The Keith Peters Building, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY UK
| | - Lidia Wrobel
- Department of Medical Genetics, Cambridge Institute for Medical Research, Cambridge, CB2 0XY UK.,UK Dementia Research Institute, The Keith Peters Building, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY UK
| | - Sandra Malmgren Hill
- Department of Medical Genetics, Cambridge Institute for Medical Research, Cambridge, CB2 0XY UK.,UK Dementia Research Institute, The Keith Peters Building, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY UK
| | - Claudia Puri
- Department of Medical Genetics, Cambridge Institute for Medical Research, Cambridge, CB2 0XY UK.,UK Dementia Research Institute, The Keith Peters Building, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY UK
| | - Sung Min Son
- Department of Medical Genetics, Cambridge Institute for Medical Research, Cambridge, CB2 0XY UK.,UK Dementia Research Institute, The Keith Peters Building, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY UK
| | - Motoki Fujimaki
- Department of Medical Genetics, Cambridge Institute for Medical Research, Cambridge, CB2 0XY UK.,UK Dementia Research Institute, The Keith Peters Building, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY UK
| | - Ye Zhu
- Department of Medical Genetics, Cambridge Institute for Medical Research, Cambridge, CB2 0XY UK.,UK Dementia Research Institute, The Keith Peters Building, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY UK
| | - Farah Siddiqi
- Department of Medical Genetics, Cambridge Institute for Medical Research, Cambridge, CB2 0XY UK.,UK Dementia Research Institute, The Keith Peters Building, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY UK
| | - Marian Fernandez-Estevez
- Department of Medical Genetics, Cambridge Institute for Medical Research, Cambridge, CB2 0XY UK.,UK Dementia Research Institute, The Keith Peters Building, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY UK
| | - Marco M Manni
- Department of Medical Genetics, Cambridge Institute for Medical Research, Cambridge, CB2 0XY UK.,UK Dementia Research Institute, The Keith Peters Building, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY UK
| | - So Jung Park
- Department of Medical Genetics, Cambridge Institute for Medical Research, Cambridge, CB2 0XY UK.,UK Dementia Research Institute, The Keith Peters Building, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY UK
| | - Julien Villeneuve
- Department of Medical Genetics, Cambridge Institute for Medical Research, Cambridge, CB2 0XY UK.,UK Dementia Research Institute, The Keith Peters Building, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY UK
| | - David Chaim Rubinsztein
- Department of Medical Genetics, Cambridge Institute for Medical Research, Cambridge, CB2 0XY UK.,UK Dementia Research Institute, The Keith Peters Building, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY UK
| |
Collapse
|
10
|
Stamatakou E, Wróbel L, Hill SM, Puri C, Son SM, Fujimaki M, Zhu Y, Siddiqi F, Fernandez-Estevez M, Manni MM, Park SJ, Villeneuve J, Rubinsztein DC. Mendelian neurodegenerative disease genes involved in autophagy. Cell Discov 2020; 6:24. [PMID: 32377374 PMCID: PMC7198619 DOI: 10.1038/s41421-020-0158-y] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2019] [Accepted: 03/11/2020] [Indexed: 12/13/2022] Open
Abstract
The lysosomal degradation pathway of macroautophagy (herein referred to as autophagy) plays a crucial role in cellular physiology by regulating the removal of unwanted cargoes such as protein aggregates and damaged organelles. Over the last five decades, significant progress has been made in understanding the molecular mechanisms that regulate autophagy and its roles in human physiology and diseases. These advances, together with discoveries in human genetics linking autophagy-related gene mutations to specific diseases, provide a better understanding of the mechanisms by which autophagy-dependent pathways can be potentially targeted for treating human diseases. Here, we review mutations that have been identified in genes involved in autophagy and their associations with neurodegenerative diseases.
Collapse
Affiliation(s)
- Eleanna Stamatakou
- Department of Medical Genetics, Cambridge Institute for Medical Research, Cambridge, CB2 0XY UK
- UK Dementia Research Institute, The Keith Peters Building, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY UK
| | - Lidia Wróbel
- Department of Medical Genetics, Cambridge Institute for Medical Research, Cambridge, CB2 0XY UK
- UK Dementia Research Institute, The Keith Peters Building, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY UK
| | - Sandra Malmgren Hill
- Department of Medical Genetics, Cambridge Institute for Medical Research, Cambridge, CB2 0XY UK
- UK Dementia Research Institute, The Keith Peters Building, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY UK
| | - Claudia Puri
- Department of Medical Genetics, Cambridge Institute for Medical Research, Cambridge, CB2 0XY UK
- UK Dementia Research Institute, The Keith Peters Building, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY UK
| | - Sung Min Son
- Department of Medical Genetics, Cambridge Institute for Medical Research, Cambridge, CB2 0XY UK
- UK Dementia Research Institute, The Keith Peters Building, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY UK
| | - Motoki Fujimaki
- Department of Medical Genetics, Cambridge Institute for Medical Research, Cambridge, CB2 0XY UK
- UK Dementia Research Institute, The Keith Peters Building, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY UK
| | - Ye Zhu
- Department of Medical Genetics, Cambridge Institute for Medical Research, Cambridge, CB2 0XY UK
- UK Dementia Research Institute, The Keith Peters Building, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY UK
| | - Farah Siddiqi
- Department of Medical Genetics, Cambridge Institute for Medical Research, Cambridge, CB2 0XY UK
- UK Dementia Research Institute, The Keith Peters Building, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY UK
| | - Marian Fernandez-Estevez
- Department of Medical Genetics, Cambridge Institute for Medical Research, Cambridge, CB2 0XY UK
- UK Dementia Research Institute, The Keith Peters Building, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY UK
| | - Marco M. Manni
- Department of Medical Genetics, Cambridge Institute for Medical Research, Cambridge, CB2 0XY UK
- UK Dementia Research Institute, The Keith Peters Building, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY UK
| | - So Jung Park
- Department of Medical Genetics, Cambridge Institute for Medical Research, Cambridge, CB2 0XY UK
- UK Dementia Research Institute, The Keith Peters Building, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY UK
| | - Julien Villeneuve
- Department of Medical Genetics, Cambridge Institute for Medical Research, Cambridge, CB2 0XY UK
- UK Dementia Research Institute, The Keith Peters Building, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY UK
| | - David Chaim Rubinsztein
- Department of Medical Genetics, Cambridge Institute for Medical Research, Cambridge, CB2 0XY UK
- UK Dementia Research Institute, The Keith Peters Building, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0XY UK
| |
Collapse
|
11
|
Takeshige-Amano H, Saiki S, Fujimaki M, Ueno SI, Li Y, Hatano T, Ishikawa KI, Oji Y, Mori A, Okuzumi A, Tsunemi T, Daida K, Ishiguro Y, Imamichi Y, Nanmo H, Nojiri S, Funayama M, Hattori N. Shared Metabolic Profile of Caffeine in Parkinsonian Disorders. Mov Disord 2020; 35:1438-1447. [PMID: 32357260 PMCID: PMC7496239 DOI: 10.1002/mds.28068] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2019] [Revised: 03/20/2020] [Accepted: 04/01/2020] [Indexed: 01/05/2023] Open
Abstract
Objective The objective of this study was to determine comprehensive metabolic changes of caffeine in the serum of patients with parkinsonian disorders including Parkinson's disease (PD), progressive supranuclear palsy (PSP), and multiple system atrophy (MSA) and to compare this with healthy control serum. Methods Serum levels of caffeine and its 11 downstream metabolites from independent double cohorts consisting of PD (n = 111, 160), PSP (n = 30, 19), MSA (n = 23, 17), and healthy controls (n = 43, 31) were examined by liquid chromatography–mass spectrometry. The association of each metabolite with clinical parameters and medication was investigated. Mutations in caffeine‐associated genes were investigated by direct sequencing. Results A total of 9 metabolites detected in more than 50% of participants in both cohorts were decreased in 3 parkinsonian disorders compared with healthy controls without any significant association with age at sampling, sex, or disease severity (Hoehn and Yahr stage and Unified Parkinson's Disease Rating Scale motor section) in PD, and levodopa dose or levodopa equivalent dose in PSP and MSA. Of the 9 detected metabolites, 8 in PD, 5 in PSP, and 3 in MSA were significantly decreased in both cohorts even after normalizing to daily caffeine consumption. No significant genetic variations in CYP1A2 or CYP2E1 were detected when compared with controls. Conclusion Serum caffeine metabolic profiles in 3 parkinsonian diseases show a high level of overlap, indicative of a common potential mechanism such as caffeine malabsorption from the small intestine, hypermetabolism, increased clearance of caffeine, and/or reduced caffeine consumption. © 2020 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
Collapse
Affiliation(s)
| | - Shinji Saiki
- Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan
| | - Motoki Fujimaki
- Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan
| | - Shin-Ichi Ueno
- Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan
| | - Yuanzhe Li
- Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan
| | - Taku Hatano
- Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan
| | - Kei-Ichi Ishikawa
- Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan
| | - Yutaka Oji
- Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan
| | - Akio Mori
- Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan
| | - Ayami Okuzumi
- Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan
| | - Taiji Tsunemi
- Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan
| | - Kensuke Daida
- Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan
| | - Yuta Ishiguro
- Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan
| | - Yoko Imamichi
- Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan
| | - Hisayoshi Nanmo
- Mathematical Science Unit, Graduate School of Engineering Science, Yokohama National University, Kanagawa, Japan
| | - Shuko Nojiri
- Medical Technology Innovation Center, Juntendo University, Tokyo, Japan
| | - Manabu Funayama
- Research Institute of Diseases of Old Age, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | - Nobutaka Hattori
- Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan
| |
Collapse
|
12
|
Ueno SI, Hatano T, Okuzumi A, Saiki S, Oji Y, Mori A, Koinuma T, Fujimaki M, Takeshige-Amano H, Kondo A, Yoshikawa N, Nojiri T, Kurano M, Yasukawa K, Yatomi Y, Ikeda H, Hattori N. Nonmercaptalbumin as an oxidative stress marker in Parkinson's and PARK2 disease. Ann Clin Transl Neurol 2020; 7:307-317. [PMID: 32059082 PMCID: PMC7086006 DOI: 10.1002/acn3.50990] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2019] [Revised: 01/15/2020] [Accepted: 01/17/2020] [Indexed: 12/20/2022] Open
Abstract
Objective To investigate the oxidized albumin ratio, which is the redox ratio of human nonmercaptalbumin (HNA) to serum albumin (%HNA), as a biomarker in idiopathic Parkinson’s disease (iPD) and related neurodegenerative disorders. Methods This prospective study enrolled 216 iPD patients, 15 patients with autosomal recessive familial PD due to parkin mutations (PARK2), 30 multiple system atrophy (MSA) patients, 32 progressive nuclear palsy (PSP) patients, and 143 healthy controls. HNA was analyzed using modified high‐performance liquid chromatography and was evaluated alongside other parameters. Results iPD and PARK2 patients had a higher %HNA than controls (iPD vs. controls: odds ratio (OR) 1.325, P < 0.001; PARK2 vs. controls: OR 1.712, P < 0.001). Even iPD patients at an early Hoehn & Yahr stage (I and II) showed a higher %HNA than controls. iPD patients had a higher %HNA than MSA and PSP patients (iPD vs. MSA: OR 1.249, P < 0.001, iPD vs. PSP: OR 1.288, P < 0.05). When discriminating iPD patients from controls, %HNA corrected by age achieved an AUC of 0.750; when discriminating iPD patients from MSA and PSP patients, an AUC of 0.747 was achieved. Furthermore, uric acid, an antioxidant compound, was decreased in iPD patients, similar to the change in %HNA. Interpretation %HNA was significantly increased in iPD and PARK2 patients compared with controls, regardless of disease course and severity. Oxidative stress might be increased from the early stages of iPD and PARK2 and play an important role in their pathomechanisms.
Collapse
Affiliation(s)
- Shin-Ichi Ueno
- Department of Neurology, Faculty of Medicine, Juntendo University, Tokyo, Japan
| | - Taku Hatano
- Department of Neurology, Faculty of Medicine, Juntendo University, Tokyo, Japan
| | - Ayami Okuzumi
- Department of Neurology, Faculty of Medicine, Juntendo University, Tokyo, Japan
| | - Shinji Saiki
- Department of Neurology, Faculty of Medicine, Juntendo University, Tokyo, Japan
| | - Yutaka Oji
- Department of Neurology, Faculty of Medicine, Juntendo University, Tokyo, Japan
| | - Akio Mori
- Department of Neurology, Faculty of Medicine, Juntendo University, Tokyo, Japan
| | - Takahiro Koinuma
- Department of Neurology, Faculty of Medicine, Juntendo University, Tokyo, Japan
| | - Motoki Fujimaki
- Department of Neurology, Faculty of Medicine, Juntendo University, Tokyo, Japan
| | | | - Akihide Kondo
- Department of Neurosurgery, Faculty of Medicine, Juntendo University, Tokyo, Japan
| | - Naoyuki Yoshikawa
- Department of Clinical Laboratory, The University of Tokyo Hospital, Tokyo, Japan
| | - Takahiro Nojiri
- Department of Clinical Laboratory, The University of Tokyo Hospital, Tokyo, Japan
| | - Makoto Kurano
- Department of Clinical Laboratory, The University of Tokyo Hospital, Tokyo, Japan
| | - Keiko Yasukawa
- Department of Clinical Laboratory, The University of Tokyo Hospital, Tokyo, Japan
| | - Yutaka Yatomi
- Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Hitoshi Ikeda
- Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Nobutaka Hattori
- Department of Neurology, Faculty of Medicine, Juntendo University, Tokyo, Japan
| |
Collapse
|
13
|
Uchiyama A, Nagatomo T, Higurashi Y, Ohnishi J, Komiyama M, Kumagai K, Fujimaki M, Yamauchi H, Tamura M, Kaneko K, Fukunishi N, Nakagawa T. Control system for the new RIKEN 28-GHz superconducting electron cyclotron resonance ion source for SRILAC. Rev Sci Instrum 2020; 91:025101. [PMID: 32113460 DOI: 10.1063/1.5129632] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/30/2019] [Accepted: 01/11/2020] [Indexed: 06/10/2023]
Abstract
A new RIKEN 28-GHz superconducting electron cyclotron resonance ion source (SC-ECRIS) has been installed for the superconducting RIKEN linear accelerator (SRILAC). The new SC-ECRIS control system mainly consists of programmable logic controllers (PLCs) embedded with the Experimental Physics and Industrial Control System. To improve the reliability as compared with previous control systems, two types of PLC central processing units, sequential and Linux, have been installed in the same unit. Past experience has shown that new types of designs that can rapidly respond to system scalability are key. By connecting PLC stations using star-topology field buses, their rapid and cost-effective response to system changes is realized for the new devices. Furthermore, a unique data acquisition system employing a 920-MHz-band radio was developed to measure analog data such as the temperature at the high-voltage stage.
Collapse
Affiliation(s)
- A Uchiyama
- Nishina Center for Accelerator Based Science, RIKEN, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - T Nagatomo
- Nishina Center for Accelerator Based Science, RIKEN, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - Y Higurashi
- Nishina Center for Accelerator Based Science, RIKEN, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - J Ohnishi
- Nishina Center for Accelerator Based Science, RIKEN, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - M Komiyama
- Nishina Center for Accelerator Based Science, RIKEN, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - K Kumagai
- Nishina Center for Accelerator Based Science, RIKEN, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - M Fujimaki
- Nishina Center for Accelerator Based Science, RIKEN, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - H Yamauchi
- SHI Accelerator Service, Ltd., 1-17-6 Osaki, Shinagawa, Tokyo 141-0032, Japan
| | - M Tamura
- SHI Accelerator Service, Ltd., 1-17-6 Osaki, Shinagawa, Tokyo 141-0032, Japan
| | - K Kaneko
- SHI Accelerator Service, Ltd., 1-17-6 Osaki, Shinagawa, Tokyo 141-0032, Japan
| | - N Fukunishi
- Nishina Center for Accelerator Based Science, RIKEN, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - T Nakagawa
- Nishina Center for Accelerator Based Science, RIKEN, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| |
Collapse
|
14
|
Nagatomo T, Higurashi Y, Ohnishi J, Uchiyama A, Fujimaki M, Kumagai K, Fukunishi N, Sakamoto N, Nakagawa T, Kamigaito O. High intensity vanadium beam for synthesis of new superheavy elements with well-controlled emittance by using "slit triplet". Rev Sci Instrum 2020; 91:023318. [PMID: 32113411 DOI: 10.1063/1.5130431] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/03/2019] [Accepted: 01/12/2020] [Indexed: 06/10/2023]
Abstract
To provide a very powerful vanadium (V) beam with an intensity of at least 6 particle μA for synthesizing a new superheavy element (SHE) with atomic number Z = 119, we have developed a high-temperature oven (HTO) system to evaporate the metallic V powder inside the new superconducting (SC) electron cyclotron ion source. We successfully extracted a V13+ beam with a maximum beam intensity of 600 eμA with 2.8-kW microwave power and 900-W heating power of the HTO. Furthermore, from a systematic study of the dependence of the beam intensity on the microwave power and the HTO power, we successfully produced a V13+ beam of 300 eμA at a consumption rate of 3 mg/h, allowing a one-month duration continuous beam to carry out the SHE synthesis. In addition, to avoid serious damage to newly introduced SC acceleration cavities by beam losses, the beam should be transported with a well-controlled emittance. To efficiently limit the beam emittance, we employed a slit triplet consisting of three pairs of slits installed around the focus point of the low-energy beam transport. The first result of the emittance reduction was observed by a pepper-pot type emittance meter as a function of the acceptance of the slit triplet.
Collapse
Affiliation(s)
- T Nagatomo
- Accelerator Group, RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - Y Higurashi
- Accelerator Group, RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - J Ohnishi
- Accelerator Group, RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - A Uchiyama
- Accelerator Group, RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - M Fujimaki
- Accelerator Group, RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - K Kumagai
- Accelerator Group, RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - N Fukunishi
- Accelerator Group, RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - N Sakamoto
- Accelerator Group, RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - T Nakagawa
- Accelerator Group, RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | - O Kamigaito
- Accelerator Group, RIKEN Nishina Center, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| |
Collapse
|
15
|
Hirano K, Fujimaki M, Sasazawa Y, Yamaguchi A, Ishikawa KI, Miyamoto K, Souma S, Furuya N, Imamichi Y, Yamada D, Saya H, Akamatsu W, Saiki S, Hattori N. Neuroprotective effects of memantine via enhancement of autophagy. Biochem Biophys Res Commun 2019; 518:161-170. [DOI: 10.1016/j.bbrc.2019.08.025] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2019] [Accepted: 08/06/2019] [Indexed: 01/12/2023]
|
16
|
Mori A, Ishikawa KI, Saiki S, Hatano T, Oji Y, Okuzumi A, Fujimaki M, Koinuma T, Ueno SI, Imamichi Y, Hattori N. Plasma metabolite biomarkers for multiple system atrophy and progressive supranuclear palsy. PLoS One 2019; 14:e0223113. [PMID: 31560709 PMCID: PMC6764690 DOI: 10.1371/journal.pone.0223113] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2019] [Accepted: 09/15/2019] [Indexed: 12/18/2022] Open
Abstract
Radiological biomarkers have been reported for multiple system atrophy and progressive supranuclear palsy, but serum/plasma biomarkers for each disorder have not been established. In this context, we performed a pilot study to identify disease-specific plasma biomarkers for multiple system atrophy and progressive supranuclear palsy. Plasma samples collected from 20 progressive supranuclear palsy patients, 16 multiple system atrophy patients and 20 controls were investigated by comprehensive metabolome analysis using capillary electrophoresis mass spectrometry and liquid chromatography mass spectrometry. Medication data were obtained from patients with multiple system atrophy and progressive supranuclear palsy, and correlations with associated metabolites were examined. Receiver operating characteristics curve analyses were used to investigate diagnostic values for each disorder. The levels of 15 and eight metabolites were significantly changed in multiple system atrophy and progressive supranuclear palsy, respectively. Multiple system atrophy was mainly characterized by elevation of long-chain fatty acids and neurosteroids, whereas progressive supranuclear palsy was characterized by changes in the level of oxidative stress-associated metabolites. Receiver operating characteristic curve analyses revealed that patients with multiple system atrophy or progressive supranuclear palsy were effectively differentiated from controls by 15 or 7 metabolites, respectively. Disease-specific metabolic changes of multiple system atrophy and progressive supranuclear palsy were identified. These biomarker sets should be replicated in a larger sample.
Collapse
Affiliation(s)
- Akio Mori
- Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan
| | - Kei-Ichi Ishikawa
- Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan
| | - Shinji Saiki
- Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan
- * E-mail: (SS); (NH)
| | - Taku Hatano
- Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan
| | - Yutaka Oji
- Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan
| | - Ayami Okuzumi
- Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan
| | - Motoki Fujimaki
- Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan
| | - Takahiro Koinuma
- Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan
| | - Shin-Ichi Ueno
- Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan
| | - Yoko Imamichi
- Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan
| | - Nobutaka Hattori
- Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan
- * E-mail: (SS); (NH)
| |
Collapse
|
17
|
Saiki S, Sasazawa Y, Fujimaki M, Kamagata K, Kaga N, Taka H, Li Y, Souma S, Hatano T, Imamichi Y, Furuya N, Mori A, Oji Y, Ueno SI, Nojiri S, Miura Y, Ueno T, Funayama M, Aoki S, Hattori N. A metabolic profile of polyamines in parkinson disease: A promising biomarker. Ann Neurol 2019; 86:251-263. [PMID: 31155745 PMCID: PMC6772170 DOI: 10.1002/ana.25516] [Citation(s) in RCA: 60] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2018] [Revised: 05/31/2019] [Accepted: 05/31/2019] [Indexed: 12/27/2022]
Abstract
Objective Aging is the highest risk factor for Parkinson disease (PD). Under physiological conditions, spermidine and spermine experimentally enhance longevity via autophagy induction. Accordingly, we evaluated the ability of each polyamine metabolite to act as an age‐related, diagnostic, and severity‐associated PD biomarker. Methods Comprehensive metabolome analysis of plasma was performed in Cohort A (controls, n = 45; PD, n = 145), followed by analysis of 7 polyamine metabolites in Cohort B (controls, n = 49; PD, n = 186; progressive supranuclear palsy, n = 19; Alzheimer disease, n = 23). Furthermore, 20 patients with PD who were successively examined within Cohort B were studied using diffusion tensor imaging (DTI). Association of each polyamine metabolite with disease severity was assessed according to Hoehn and Yahr stage (H&Y) and Unified Parkinson's Disease Rating Scale motor section (UPDRS‐III). Additionally, the autophagy induction ability of each polyamine metabolite was examined in vitro in various cell lines. Results In Cohort A, N8‐acetylspermidine and N‐acetylputrescine levels were significantly and mildly elevated in PD, respectively. In Cohort B, spermine levels and spermine/spermidine ratio were significantly reduced in PD, concomitant with hyperacetylation. Furthermore, N1,N8‐diacetylspermidine levels had the highest diagnostic value, and correlated with H&Y, UPDRS‐III, and axonal degeneration quantified by DTI. The spermine/spermidine ratio in controls declined with age, but was consistently suppressed in PD. Among polyamine metabolites, spermine was the strongest autophagy inducer, especially in SH‐SY5Y cells. No significant genetic variations in 5 genes encoding enzymes associated with spermine/spermidine metabolism were detected compared with controls. Interpretation Spermine synthesis and N1,N8‐diacetylspermidine may respectively be useful diagnostic and severity‐associated biomarkers for PD. ANN NEUROL 2019;86:251–263
Collapse
Affiliation(s)
- Shinji Saiki
- Department of Neurology, Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - Yukiko Sasazawa
- Department of Neurology, Juntendo University Graduate School of Medicine, Tokyo, Japan.,Research Institute for Diseases of Old Age, Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - Motoki Fujimaki
- Department of Neurology, Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - Koji Kamagata
- Department of Radiology, Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - Naoko Kaga
- Laboratory of Proteomics and Biomolecular Science, Research Support Center, Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - Hikari Taka
- Laboratory of Proteomics and Biomolecular Science, Research Support Center, Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - Yuanzhe Li
- Department of Neurology, Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - Sanae Souma
- Department of Neurology, Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - Taku Hatano
- Department of Neurology, Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - Yoko Imamichi
- Department of Neurology, Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - Norihiko Furuya
- Department of Neurology, Juntendo University Graduate School of Medicine, Tokyo, Japan.,Division for Development of Autophagy Modulating Drugs, Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - Akio Mori
- Department of Neurology, Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - Yutaka Oji
- Department of Neurology, Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - Shin-Ichi Ueno
- Department of Neurology, Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - Shuko Nojiri
- Clinical Research Center, Juntendo University, Tokyo, Japan
| | - Yoshiki Miura
- Laboratory of Proteomics and Biomolecular Science, Research Support Center, Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - Takashi Ueno
- Laboratory of Proteomics and Biomolecular Science, Research Support Center, Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - Manabu Funayama
- Department of Neurology, Juntendo University Graduate School of Medicine, Tokyo, Japan.,Research Institute for Diseases of Old Age, Juntendo University Graduate School of Medicine, Tokyo, Japan.,Laboratory of Genomic Medicine, Center for Genomic and Regenerative Medicine, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| | - Shigeki Aoki
- Department of Radiology, Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - Nobutaka Hattori
- Department of Neurology, Juntendo University Graduate School of Medicine, Tokyo, Japan.,Research Institute for Diseases of Old Age, Juntendo University Graduate School of Medicine, Tokyo, Japan.,Division for Development of Autophagy Modulating Drugs, Juntendo University Graduate School of Medicine, Tokyo, Japan.,Laboratory of Genomic Medicine, Center for Genomic and Regenerative Medicine, Graduate School of Medicine, Juntendo University, Tokyo, Japan
| |
Collapse
|
18
|
Okuzumi A, Hatano T, Ueno SI, Ogawa T, Saiki S, Mori A, Koinuma T, Oji Y, Ishikawa KI, Fujimaki M, Sato S, Ramamoorthy S, Mohney RP, Hattori N. Metabolomics-based identification of metabolic alterations in PARK2. Ann Clin Transl Neurol 2019; 6:525-536. [PMID: 30911576 PMCID: PMC6414487 DOI: 10.1002/acn3.724] [Citation(s) in RCA: 31] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2018] [Accepted: 12/31/2018] [Indexed: 12/05/2022] Open
Abstract
Objective Parkin is the causative gene for autosomal recessive familial Parkinson's disease (PD), although it remains unclear how parkin dysfunction is involved with the general condition. Recently, serum and/or plasma metabolomics revealed alterations in metabolic pathways that might reflect pathomechanisms of idiopathic PD (iPD). Thus, we hypothesized that serum metabolomics of patients with homozygous or compound heterozygous parkin mutations (namely, PARK2) might reflect metabolic alterations due to parkin dysfunction. Methods We enrolled 15 PARK2 patients (52 ± 17.6 years) confirmed with homozygous (seven cases) and compound heterozygous (eight cases) parkin mutations, along with 19 healthy age‐matched controls (51 ± 11.5 years). We analyzed 830 metabolites from participants’ serum using well‐established metabolomics technologies, including ultra‐high performance liquid chromatography/tandem mass spectroscopy. Results Based on metabolic profiles, hierarchical matrix analysis can divide samples between control and PARK2 subjects. Profiles from PARK2 patients showed significantly higher levels of fatty acid (FA) metabolites and oxidized lipids, and significantly lower levels of antioxidant, caffeine, and benzoate‐related metabolites. Interpretation Metabolomics can identify specific metabolic alterations in PARK2 patients compared with controls. Alterations in FA metabolites suggest a relationship between parkin function and lipid metabolism. The elevation of oxidized lipids in combination with decreasing antioxidants may reflect general hyperoxidative stress. Decreasing benzoate‐related metabolites might be due to the alteration in gut microbiota. Consequently, caffeine and its metabolites may be decreased due to malabsorption. These findings are similar to metabolic alterations in iPD. Thus, serum/plasma metabolomics may reflect the association between parkin dysfunction and parkinsonism.
Collapse
Affiliation(s)
- Ayami Okuzumi
- Department of Neurology Juntendo University School of Medicine Tokyo Japan
| | - Taku Hatano
- Department of Neurology Juntendo University School of Medicine Tokyo Japan
| | - Shin-Ichi Ueno
- Department of Neurology Juntendo University School of Medicine Tokyo Japan
| | - Takashi Ogawa
- Department of Neurology Juntendo University School of Medicine Tokyo Japan
| | - Shinji Saiki
- Department of Neurology Juntendo University School of Medicine Tokyo Japan
| | - Akio Mori
- Department of Neurology Juntendo University School of Medicine Tokyo Japan
| | - Takahiro Koinuma
- Department of Neurology Juntendo University School of Medicine Tokyo Japan
| | - Yutaka Oji
- Department of Neurology Juntendo University School of Medicine Tokyo Japan
| | - Kei-Ichi Ishikawa
- Department of Neurology Juntendo University School of Medicine Tokyo Japan
| | - Motoki Fujimaki
- Department of Neurology Juntendo University School of Medicine Tokyo Japan
| | - Shigeto Sato
- Department of Neurology Juntendo University School of Medicine Tokyo Japan
| | | | | | - Nobutaka Hattori
- Department of Neurology Juntendo University School of Medicine Tokyo Japan
| |
Collapse
|
19
|
Ueno SI, Saiki S, Fujimaki M, Takeshige-Amano H, Hatano T, Oyama G, Ishikawa KI, Yamaguchi A, Nojiri S, Akamatsu W, Hattori N. Zonisamide Administration Improves Fatty Acid β-Oxidation in Parkinson's Disease. Cells 2018; 8:cells8010014. [PMID: 30597973 PMCID: PMC6356654 DOI: 10.3390/cells8010014] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2018] [Revised: 12/20/2018] [Accepted: 12/25/2018] [Indexed: 12/03/2022] Open
Abstract
Although many experimental studies have shown the favorable effects of zonisamide on mitochondria using models of Parkinson’s disease (PD), the influence of zonisamide on metabolism in PD patients remains unclear. To assess metabolic status under zonisamide treatment in PD, we performed a pilot study using a comprehensive metabolome analysis. Plasma samples were collected for at least one year from 30 patients with PD: 10 without zonisamide medication and 20 with zonisamide medication. We performed comprehensive metabolome analyses of plasma with capillary electrophoresis time-of-flight mass spectrometry and liquid chromatography time-of-flight mass spectrometry. We also measured disease severity using Hoehn and Yahr (H&Y) staging and the Unified Parkinson’s Disease Rating Scale (UPDRS) motor section, and analyzed blood chemistry. In PD with zonisamide treatment, 15 long-chain acylcarnitines (LCACs) tended to be increased, of which four (AC(12:0), AC(12:1)-1, AC(16:1), and AC(16:2)) showed statistical significance. Of these, two LCACs (AC(16:1) and AC(16:2)) were also identified by partial least squares analysis. There was no association of any LCAC with age, disease severity, levodopa daily dose, or levodopa equivalent dose. Because an upregulation of LCACs implies improvement of mitochondrial β-oxidation, zonisamide might be beneficial for mitochondrial β-oxidation, which is suppressed in PD.
Collapse
Affiliation(s)
- Shin-Ichi Ueno
- Department of Neurology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan.
| | - Shinji Saiki
- Department of Neurology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan.
| | - Motoki Fujimaki
- Department of Neurology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan.
| | - Haruka Takeshige-Amano
- Department of Neurology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan.
| | - Taku Hatano
- Department of Neurology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan.
| | - Genko Oyama
- Department of Neurology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan.
| | - Kei-Ichi Ishikawa
- Department of Neurology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan.
- Center for Genomic and Regenerative Medicine, Juntendo University School of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan.
| | - Akihiro Yamaguchi
- Center for Genomic and Regenerative Medicine, Juntendo University School of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan.
| | - Shuko Nojiri
- Medical Technology Innovation Center, Juntendo University, Bunkyo-ku, Tokyo 113-8421, Japan.
| | - Wado Akamatsu
- Center for Genomic and Regenerative Medicine, Juntendo University School of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan.
| | - Nobutaka Hattori
- Department of Neurology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo 113-8421, Japan.
| |
Collapse
|
20
|
Fujimaki M, Saiki S, Li Y, Kaga N, Taka H, Hatano T, Ishikawa KI, Oji Y, Mori A, Okuzumi A, Koinuma T, Ueno SI, Imamichi Y, Ueno T, Miura Y, Funayama M, Hattori N. Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease. Neurology 2018; 90:e404-e411. [PMID: 29298852 PMCID: PMC5791797 DOI: 10.1212/wnl.0000000000004888] [Citation(s) in RCA: 52] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2017] [Accepted: 09/29/2017] [Indexed: 12/29/2022] Open
Abstract
Objective To investigate the kinetics and metabolism of caffeine in serum from patients with Parkinson disease (PD) and controls using liquid chromatography–mass spectrometry. Methods Levels of caffeine and its 11 metabolites in serum from 108 patients with PD and 31 age-matched healthy controls were examined by liquid chromatography–mass spectrometry. Mutations in caffeine-associated genes were screened by direct sequencing. Results Serum levels of caffeine and 9 of its downstream metabolites were significantly decreased even in patients with early PD, unrelated to total caffeine intake or disease severity. No significant genetic variations in CYP1A2 or CYP2E1, encoding cytochrome P450 enzymes primarily involved in metabolizing caffeine in humans, were detected compared with controls. Likewise, caffeine concentrations in patients with PD with motor complications were significantly decreased compared with those without motor complications. No associations between disease severity and single nucleotide variants of the ADORA2A gene encoding adenosine 2A receptor were detected, implying a dissociation of receptor sensitivity changes and phenotype. The profile of serum caffeine and metabolite levels was identified as a potential diagnostic biomarker by receiver operating characteristic curve analysis. Conclusion Absolute lower levels of caffeine and caffeine metabolite profiles are promising diagnostic biomarkers for early PD. This is consistent with the neuroprotective effect of caffeine previously revealed by epidemiologic and experimental studies. Classification of evidence This study provides Class III evidence that decreased serum levels of caffeine and its metabolites identify patients with PD.
Collapse
Affiliation(s)
- Motoki Fujimaki
- From the Department of Neurology (M.F., S.S., Y.L., T.H., K.-I.I., Y.O., A.M., A.O., T.K., S.-I.U., Y.I., M.F., N.H.), Research Institute for Diseases of Old Age (M.F., N.H.), and Laboratory of Proteomics and Biomolecular Science (N.K., H.T., T.U., Y.M.), Juntendo University School of Medicine, Tokyo, Japan
| | - Shinji Saiki
- From the Department of Neurology (M.F., S.S., Y.L., T.H., K.-I.I., Y.O., A.M., A.O., T.K., S.-I.U., Y.I., M.F., N.H.), Research Institute for Diseases of Old Age (M.F., N.H.), and Laboratory of Proteomics and Biomolecular Science (N.K., H.T., T.U., Y.M.), Juntendo University School of Medicine, Tokyo, Japan.
| | - Yuanzhe Li
- From the Department of Neurology (M.F., S.S., Y.L., T.H., K.-I.I., Y.O., A.M., A.O., T.K., S.-I.U., Y.I., M.F., N.H.), Research Institute for Diseases of Old Age (M.F., N.H.), and Laboratory of Proteomics and Biomolecular Science (N.K., H.T., T.U., Y.M.), Juntendo University School of Medicine, Tokyo, Japan
| | - Naoko Kaga
- From the Department of Neurology (M.F., S.S., Y.L., T.H., K.-I.I., Y.O., A.M., A.O., T.K., S.-I.U., Y.I., M.F., N.H.), Research Institute for Diseases of Old Age (M.F., N.H.), and Laboratory of Proteomics and Biomolecular Science (N.K., H.T., T.U., Y.M.), Juntendo University School of Medicine, Tokyo, Japan
| | - Hikari Taka
- From the Department of Neurology (M.F., S.S., Y.L., T.H., K.-I.I., Y.O., A.M., A.O., T.K., S.-I.U., Y.I., M.F., N.H.), Research Institute for Diseases of Old Age (M.F., N.H.), and Laboratory of Proteomics and Biomolecular Science (N.K., H.T., T.U., Y.M.), Juntendo University School of Medicine, Tokyo, Japan
| | - Taku Hatano
- From the Department of Neurology (M.F., S.S., Y.L., T.H., K.-I.I., Y.O., A.M., A.O., T.K., S.-I.U., Y.I., M.F., N.H.), Research Institute for Diseases of Old Age (M.F., N.H.), and Laboratory of Proteomics and Biomolecular Science (N.K., H.T., T.U., Y.M.), Juntendo University School of Medicine, Tokyo, Japan
| | - Kei-Ichi Ishikawa
- From the Department of Neurology (M.F., S.S., Y.L., T.H., K.-I.I., Y.O., A.M., A.O., T.K., S.-I.U., Y.I., M.F., N.H.), Research Institute for Diseases of Old Age (M.F., N.H.), and Laboratory of Proteomics and Biomolecular Science (N.K., H.T., T.U., Y.M.), Juntendo University School of Medicine, Tokyo, Japan
| | - Yutaka Oji
- From the Department of Neurology (M.F., S.S., Y.L., T.H., K.-I.I., Y.O., A.M., A.O., T.K., S.-I.U., Y.I., M.F., N.H.), Research Institute for Diseases of Old Age (M.F., N.H.), and Laboratory of Proteomics and Biomolecular Science (N.K., H.T., T.U., Y.M.), Juntendo University School of Medicine, Tokyo, Japan
| | - Akio Mori
- From the Department of Neurology (M.F., S.S., Y.L., T.H., K.-I.I., Y.O., A.M., A.O., T.K., S.-I.U., Y.I., M.F., N.H.), Research Institute for Diseases of Old Age (M.F., N.H.), and Laboratory of Proteomics and Biomolecular Science (N.K., H.T., T.U., Y.M.), Juntendo University School of Medicine, Tokyo, Japan
| | - Ayami Okuzumi
- From the Department of Neurology (M.F., S.S., Y.L., T.H., K.-I.I., Y.O., A.M., A.O., T.K., S.-I.U., Y.I., M.F., N.H.), Research Institute for Diseases of Old Age (M.F., N.H.), and Laboratory of Proteomics and Biomolecular Science (N.K., H.T., T.U., Y.M.), Juntendo University School of Medicine, Tokyo, Japan
| | - Takahiro Koinuma
- From the Department of Neurology (M.F., S.S., Y.L., T.H., K.-I.I., Y.O., A.M., A.O., T.K., S.-I.U., Y.I., M.F., N.H.), Research Institute for Diseases of Old Age (M.F., N.H.), and Laboratory of Proteomics and Biomolecular Science (N.K., H.T., T.U., Y.M.), Juntendo University School of Medicine, Tokyo, Japan
| | - Shin-Ichi Ueno
- From the Department of Neurology (M.F., S.S., Y.L., T.H., K.-I.I., Y.O., A.M., A.O., T.K., S.-I.U., Y.I., M.F., N.H.), Research Institute for Diseases of Old Age (M.F., N.H.), and Laboratory of Proteomics and Biomolecular Science (N.K., H.T., T.U., Y.M.), Juntendo University School of Medicine, Tokyo, Japan
| | - Yoko Imamichi
- From the Department of Neurology (M.F., S.S., Y.L., T.H., K.-I.I., Y.O., A.M., A.O., T.K., S.-I.U., Y.I., M.F., N.H.), Research Institute for Diseases of Old Age (M.F., N.H.), and Laboratory of Proteomics and Biomolecular Science (N.K., H.T., T.U., Y.M.), Juntendo University School of Medicine, Tokyo, Japan
| | - Takashi Ueno
- From the Department of Neurology (M.F., S.S., Y.L., T.H., K.-I.I., Y.O., A.M., A.O., T.K., S.-I.U., Y.I., M.F., N.H.), Research Institute for Diseases of Old Age (M.F., N.H.), and Laboratory of Proteomics and Biomolecular Science (N.K., H.T., T.U., Y.M.), Juntendo University School of Medicine, Tokyo, Japan
| | - Yoshiki Miura
- From the Department of Neurology (M.F., S.S., Y.L., T.H., K.-I.I., Y.O., A.M., A.O., T.K., S.-I.U., Y.I., M.F., N.H.), Research Institute for Diseases of Old Age (M.F., N.H.), and Laboratory of Proteomics and Biomolecular Science (N.K., H.T., T.U., Y.M.), Juntendo University School of Medicine, Tokyo, Japan
| | - Manabu Funayama
- From the Department of Neurology (M.F., S.S., Y.L., T.H., K.-I.I., Y.O., A.M., A.O., T.K., S.-I.U., Y.I., M.F., N.H.), Research Institute for Diseases of Old Age (M.F., N.H.), and Laboratory of Proteomics and Biomolecular Science (N.K., H.T., T.U., Y.M.), Juntendo University School of Medicine, Tokyo, Japan
| | - Nobutaka Hattori
- From the Department of Neurology (M.F., S.S., Y.L., T.H., K.-I.I., Y.O., A.M., A.O., T.K., S.-I.U., Y.I., M.F., N.H.), Research Institute for Diseases of Old Age (M.F., N.H.), and Laboratory of Proteomics and Biomolecular Science (N.K., H.T., T.U., Y.M.), Juntendo University School of Medicine, Tokyo, Japan.
| |
Collapse
|
21
|
Akio M, Hatano T, Saiki S, Ishikawa K, Oji Y, Okuzumi A, Fujimaki M, Koinuma T, Hattori N. Plasma metabolomics reveals low levels of antioxidants in PSP. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.1647] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
22
|
Saiki S, Hatano T, Fujimaki M, Ishikawa KI, Mori A, Oji Y, Okuzumi A, Fukuhara T, Koinuma T, Imamichi Y, Nagumo M, Furuya N, Nojiri S, Amo T, Yamashiro K, Hattori N. Decreased long-chain acylcarnitines from insufficient β-oxidation as potential early diagnostic markers for Parkinson's disease. Sci Rep 2017; 7:7328. [PMID: 28779141 PMCID: PMC5544708 DOI: 10.1038/s41598-017-06767-y] [Citation(s) in RCA: 69] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2017] [Accepted: 06/19/2017] [Indexed: 01/09/2023] Open
Abstract
Increasing evidence shows that metabolic abnormalities in body fluids are distinguishing features of the pathophysiology of Parkinson’s disease. However, a non-invasive approach has not been established in the earliest or pre-symptomatic phases. Here, we report comprehensive double-cohort analyses of the metabolome using capillary electrophoresis/liquid chromatography mass-spectrometry. The plasma analyses identified 18 Parkinson’s disease-specific metabolites and revealed decreased levels of seven long-chain acylcarnitines in two Parkinson’s disease cohorts (n = 109, 145) compared with controls (n = 32, 45), respectively. Furthermore, statistically significant decreases in five long-chain acylcarnitines were detected in Hoehn and Yahr stage I. Likewise, decreased levels of acylcarnitine(16:0), a decreased ratio of acylcarnitine(16:0) to fatty acid(16:0), and an increased index of carnitine palmitoyltransferase 1 were identified in Hoehn and Yahr stage I of both cohorts, suggesting of initial β-oxidation suppression. Receiver operating characteristic curves produced using 12–14 long-chain acylcarnitines provided a large area of under the curve, high specificity and moderate sensitivity for diagnosing Parkinson’s disease. Our data demonstrate that a primary decrement of mitochondrial β-oxidation and that 12–14 long-chain acylcarnitines decreases would be promising diagnostic biomarkers for Parkinson’s disease.
Collapse
Affiliation(s)
- Shinji Saiki
- Department of Neurology, Juntendo University School of Medicine, Bunkyo, Tokyo, 113-8421, Japan
| | - Taku Hatano
- Department of Neurology, Juntendo University School of Medicine, Bunkyo, Tokyo, 113-8421, Japan
| | - Motoki Fujimaki
- Department of Neurology, Juntendo University School of Medicine, Bunkyo, Tokyo, 113-8421, Japan
| | - Kei-Ichi Ishikawa
- Department of Neurology, Juntendo University School of Medicine, Bunkyo, Tokyo, 113-8421, Japan
| | - Akio Mori
- Department of Neurology, Juntendo University School of Medicine, Bunkyo, Tokyo, 113-8421, Japan
| | - Yutaka Oji
- Department of Neurology, Juntendo University School of Medicine, Bunkyo, Tokyo, 113-8421, Japan
| | - Ayami Okuzumi
- Department of Neurology, Juntendo University School of Medicine, Bunkyo, Tokyo, 113-8421, Japan
| | - Takeshi Fukuhara
- Department of Neurology, Juntendo University School of Medicine, Bunkyo, Tokyo, 113-8421, Japan
| | - Takahiro Koinuma
- Department of Neurology, Juntendo University School of Medicine, Bunkyo, Tokyo, 113-8421, Japan
| | - Yoko Imamichi
- Department of Neurology, Juntendo University School of Medicine, Bunkyo, Tokyo, 113-8421, Japan
| | - Miho Nagumo
- Department of Neurology, Juntendo University School of Medicine, Bunkyo, Tokyo, 113-8421, Japan
| | - Norihiko Furuya
- Department of Neurology, Juntendo University School of Medicine, Bunkyo, Tokyo, 113-8421, Japan.,Department of Research and Therapeutics for Movement Disorders, Juntendo University School of Medicine, Bunkyo, Tokyo, 113-8421, Japan
| | - Shuko Nojiri
- Clinical Research Center, Juntendo University, Bunkyo, Tokyo, 113-8421, Japan
| | - Taku Amo
- Department of Applied Chemistry, National Defense Academy, Yokosuka, Kanagawa, 239-8686, Japan
| | - Kazuo Yamashiro
- Department of Neurology, Juntendo University School of Medicine, Bunkyo, Tokyo, 113-8421, Japan
| | - Nobutaka Hattori
- Department of Neurology, Juntendo University School of Medicine, Bunkyo, Tokyo, 113-8421, Japan. .,Department of Research and Therapeutics for Movement Disorders, Juntendo University School of Medicine, Bunkyo, Tokyo, 113-8421, Japan.
| |
Collapse
|
23
|
Fujimaki M, Kanai K, Funabe S, Takanashi M, Yokoyama K, Li Y, Hattori N. Parkinsonism in a patient with valosin-containing protein gene mutation showing: a case report. J Neurol 2017; 264:1284-1286. [PMID: 28364293 DOI: 10.1007/s00415-017-8467-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2016] [Revised: 03/18/2017] [Accepted: 03/20/2017] [Indexed: 12/13/2022]
Affiliation(s)
- Motoki Fujimaki
- Department of Neurology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyouku, Tokyo, 113-8431, Japan
| | - Kazuaki Kanai
- Department of Neurology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyouku, Tokyo, 113-8431, Japan.
| | - Sayaka Funabe
- Department of Neurology, Sendai Nishitaga National Hospital, Sendai, Miyagi, Japan
| | - Masashi Takanashi
- Department of Neurology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyouku, Tokyo, 113-8431, Japan
| | - Kazumasa Yokoyama
- Department of Neurology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyouku, Tokyo, 113-8431, Japan
| | - Yuanzhe Li
- Department of Neurology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyouku, Tokyo, 113-8431, Japan
| | - Nobutaka Hattori
- Department of Neurology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyouku, Tokyo, 113-8431, Japan
| |
Collapse
|
24
|
Abstract
Renal cell carcinoma (RCC) patients who develop a paraneoplastic syndrome may present with neuromuscular disorders. We herein report the case of a 50-year-old man who suffered from progressive gait disturbance and muscle weakness. The results of a nerve conduction study fulfilled the criteria of chronic inflammatory demyelinating polyneuropathy. An abdominal CT scan detected RCC, the pathological diagnosis of which was clear cell type. After tumor resection and a single course of intravenous immunoglobulin therapy, the patient's symptoms drastically improved over the course of one year. The patient's neurological symptoms preceded the detection of cancer. A proper diagnosis and the initiation of suitable therapies resulted in a favorable outcome.
Collapse
Affiliation(s)
- Kenya Nishioka
- Department of Neurology, Juntendo University School of Medicine, Japan
| | | | | | | | | | | | | | | |
Collapse
|
25
|
Fujimaki M, Takanashi M, Kobayashi M, Wada KI, Machida Y, Kondo A, Hattori N, Miwa H. Cerebrospinal fluid dissemination of anaplastic intraventricular meningioma: report of a case presenting with progressive brainstem dysfunction and multiple cranial nerve palsies. BMC Neurol 2016; 16:82. [PMID: 27245327 PMCID: PMC4886413 DOI: 10.1186/s12883-016-0611-6] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2015] [Accepted: 05/27/2016] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND It is extremely rare to see cerebrospinal fluid dissemination of intraventricular meningioma, particularly with the development of acute, progressive brainstem/cerebellar dysfunction with an absence of mass formation in the corresponding anatomical sites. CASE PRESENTATION An 81-year-old man was admitted because of double vision, right facial nerve palsy and truncal ataxia. Brain magnetic resonance imaging showed normal findings except for a tumor mass in the left lateral ventricle, which had been noted over 6 months previously. The patient developed hiccups, hyperventilation, and drowsiness, which worsened progressively, and did not respond to corticosteroid or intraventricular immunoglobulin therapy. Cerebrospinal fluid study revealed a mild elevation of protein, and cytology was negative. The patient died and an autopsy was performed. Postmortem investigation disclosed a malignant transformation of benign fibroid meningioma with cerebrospinal fluid dissemination of the malignant cells, diversely involving the surface of brainstem, cerebellum, and spinal cords, secondarily resulting in extensive ischemia in the brain parenchyma by vessel occlusion. CONCLUSION If a patient with an intraventricular tumor develops acute, progressive neurological symptoms, the possibility that it is be caused by cerebrospinal fluid dissemination of tumor cells, after malignant transformation, should be considered.
Collapse
Affiliation(s)
- Motoki Fujimaki
- Department of Neurology, Juntendo University Nerima Hospital, 3-1-10 Takanodai, Nerimaku, Tokyo, 177-8521, Japan. .,Department of Neurology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyouku, Tokyo, 113-8431, Japan. .,, Postal Address: 2-1-1 Hongo, Bunkyouku, Tokyo, 113-8431, Japan.
| | - Masashi Takanashi
- Department of Neurology, Juntendo University Nerima Hospital, 3-1-10 Takanodai, Nerimaku, Tokyo, 177-8521, Japan
| | - Manami Kobayashi
- Department of Neurology, Juntendo University Nerima Hospital, 3-1-10 Takanodai, Nerimaku, Tokyo, 177-8521, Japan.,Department of Neurology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyouku, Tokyo, 113-8431, Japan
| | - Kei-ichiro Wada
- Department of Neurology, Juntendo University Nerima Hospital, 3-1-10 Takanodai, Nerimaku, Tokyo, 177-8521, Japan
| | - Yutaka Machida
- Department of Neurology, Juntendo University Nerima Hospital, 3-1-10 Takanodai, Nerimaku, Tokyo, 177-8521, Japan
| | - Akihide Kondo
- Department of Neurosurgery, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyouku, Tokyo, 113-8431, Japan
| | - Nobutaka Hattori
- Department of Neurology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyouku, Tokyo, 113-8431, Japan
| | - Hideto Miwa
- Department of Neurology, Juntendo University Nerima Hospital, 3-1-10 Takanodai, Nerimaku, Tokyo, 177-8521, Japan
| |
Collapse
|
26
|
Fujimaki M, Kawajiri S, Ichikawa K, Tomizawa Y, Nakazato T, Noda K, Hattori N, Koike M, Okuma Y. Lymphomatoid Granulomatosis with Central Nervous System Involvement Successfully Treated with Cyclophosphamide, High-dose Cytarabine, Dexamethasone, Etoposide, and Rituximab (CHASER therapy) Followed by Brain Irradiation: A Case Study. CNS Neurosci Ther 2016; 21:610-2. [PMID: 26096049 DOI: 10.1111/cns.12414] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2015] [Revised: 05/04/2015] [Accepted: 05/06/2015] [Indexed: 11/27/2022] Open
Affiliation(s)
- Motoki Fujimaki
- Department of Neurology, Juntendo University Shizuoka Hospital, Izunokuni, Japan.,Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan
| | - Sumihiro Kawajiri
- Department of Neurology, Juntendo University Shizuoka Hospital, Izunokuni, Japan
| | - Kunimoto Ichikawa
- Department of Hematology, Juntendo University Shizuoka Hospital, Izunokuni, Japan
| | - Yuji Tomizawa
- Department of Neurology, Juntendo University Shizuoka Hospital, Izunokuni, Japan
| | - Tomoko Nakazato
- Department of Neurology, Juntendo University Shizuoka Hospital, Izunokuni, Japan.,Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan
| | - Kazuyuki Noda
- Department of Neurology, Juntendo University Shizuoka Hospital, Izunokuni, Japan
| | - Nobutaka Hattori
- Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan
| | - Michiaki Koike
- Department of Hematology, Juntendo University Shizuoka Hospital, Izunokuni, Japan
| | - Yasuyuki Okuma
- Department of Neurology, Juntendo University Shizuoka Hospital, Izunokuni, Japan
| |
Collapse
|
27
|
Ueno S, Tsuboi S, Fujimaki M, Eguchi H, Machida Y, Hattori N, Miwa H. Acute psychosis as an initial manifestation of hypothyroidism: a case report. J Med Case Rep 2015; 9:264. [PMID: 26577152 PMCID: PMC4650306 DOI: 10.1186/s13256-015-0744-z] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2015] [Accepted: 10/23/2015] [Indexed: 11/28/2022] Open
Abstract
Introduction Hypothyroidism is one of the most important causes of treatable dementia, and psychosis occasionally associated with it is known as myxedema madness. We report a case of a 90-year-old patient who developed myxedema madness acutely without overt clinical symptoms and signs suggestive of hypothyroidism. Case presentation A 90-year-old Japanese man, a general practitioner, was admitted to our emergency room because of acute-onset lethargy, delusions, and hallucinations. He had been actively working until 3 days before the admission. Upon admission, his general physical examination was unremarkable. However, a blood investigation showed the presence of hypothyroidism, and computed tomography revealed pleural effusion and ascites. Electroencephalography revealed diffuse slow waves with a decrease of α-wave activity. A single-photon emission computed tomography scan revealed a decrease of cerebral blood flow in both frontal lobes. The patient was soon treated with thyroid hormone replacement therapy. Following normalization of his thyroid function, both pleural effusion and ascites diminished and his electroencephalographic activity improved simultaneously; however, he did not recover from his psychosis. Conclusions Myxedema madness should be kept in mind in the differential diagnosis of acute psychosis in elderly patients, particularly the oldest patients as in our case, because manifestations of hypothyroidism often may be indistinguishable from the aging process.
Collapse
Affiliation(s)
- Shinichi Ueno
- Department of Neurology, Juntendo University Nerima Hospital, 3-1-10 Takanodai, Nerima, Tokyo, 177-8521, Japan
| | - Satoko Tsuboi
- Department of Neurology, Juntendo University Nerima Hospital, 3-1-10 Takanodai, Nerima, Tokyo, 177-8521, Japan
| | - Motoki Fujimaki
- Department of Neurology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo, Tokyo, 113-8421, Japan
| | - Hiroto Eguchi
- Department of Neurology, Juntendo University Nerima Hospital, 3-1-10 Takanodai, Nerima, Tokyo, 177-8521, Japan
| | - Yutaka Machida
- Department of Neurology, Juntendo University Nerima Hospital, 3-1-10 Takanodai, Nerima, Tokyo, 177-8521, Japan
| | - Nobutaka Hattori
- Department of Neurology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo, Tokyo, 113-8421, Japan
| | - Hideto Miwa
- Department of Neurology, Juntendo University Nerima Hospital, 3-1-10 Takanodai, Nerima, Tokyo, 177-8521, Japan.
| |
Collapse
|
28
|
Yokoyama J, Ohba S, Fujimaki M, Anzai T, Kojima M, Ikeda K, Suzuki M, Yoshimoto H, Inoue K. Impact of intra-arterial chemotherapy including internal carotid artery for advanced paranasal sinus cancers involving the skull base. Br J Cancer 2014; 111:2229-34. [PMID: 25255100 PMCID: PMC4264436 DOI: 10.1038/bjc.2014.501] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2014] [Revised: 06/02/2014] [Accepted: 08/18/2014] [Indexed: 11/29/2022] Open
Abstract
Background: The most significant problem of intra-arterial chemotherapy for advanced paranasal sinus carcinomas and residual cancers supplied by internal carotid artery (ICA) and involving the skull base is the lack of salvage therapies. Objective: The objective of the study was to evaluate the usefulness of intra-arterial chemotherapy including ICA infusion for treating advanced paranasal sinus carcinomas, which have invaded the skull base. Methods: Forty-six patients with advanced paranasal sinus carcinomas supplied by ICA were treated by intra-arterial chemotherapy using CDDP and sodium thiosulphate (STS) as a neutraliser of CDDP toxicity. After evaluating CT angiography, 150 mg m−2 of CDDP was superselectively administered weekly to each feeding artery including ICA four times. Results: The 10-year overall survival rate and progression-free survival rate were 70.7 and 60.2%, respectively. Compared with control group without infusing ICA, recurrences at anterior skullbase or anterior ethomoid sinus were significantly diminished. Of 32 patients in which the orbital apex had been invaded, 29 patients were treated with successful preservation of orbital contents. The CT angiography could efficiently determine all feeding arteries supplying the cancers. Consequently, chemotherapy could be administered on schedule, and side effects were minimal and acceptable. Conclusions: This new method has promising applications in the treatment of advanced paranasal sinus carcinomas involving the skull base.
Collapse
Affiliation(s)
- J Yokoyama
- Department of Otolaryngology, Head and Neck Surgery, Juntendo University School of Medicine, Tokyo, Japan
| | - S Ohba
- Department of Otolaryngology, Head and Neck Surgery, Juntendo University School of Medicine, Tokyo, Japan
| | - M Fujimaki
- Department of Otolaryngology, Head and Neck Surgery, Juntendo University School of Medicine, Tokyo, Japan
| | - T Anzai
- Department of Otolaryngology, Head and Neck Surgery, Juntendo University School of Medicine, Tokyo, Japan
| | - M Kojima
- Department of Otolaryngology, Head and Neck Surgery, Juntendo University School of Medicine, Tokyo, Japan
| | - K Ikeda
- Department of Otolaryngology, Head and Neck Surgery, Juntendo University School of Medicine, Tokyo, Japan
| | - M Suzuki
- Department of Radiology, Juntendo University School of Medicine, Tokyo, Japan
| | - H Yoshimoto
- Second Department of Oral Maxillofacial Surgery, Osaka Dental University, Osaka, Japan
| | - K Inoue
- Department of radiology, Tochigi Cancer Center, Utsunomiya, Japan
| |
Collapse
|
29
|
Inoue Y, Kokuba Y, Katsura T, Fujimaki M, Kajiwara K. PP227-MON: Can Lipid Emulsion be Administered as Secondary Piggyback Infusion Through Primary TPN Infusion Line? – Studies for the Changes of Lipid Particle Size. Clin Nutr 2014. [DOI: 10.1016/s0261-5614(14)50561-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
30
|
Kanai K, Yokota T, Shibuya K, Kanouchi T, Iwai Y, Misawa S, Oyama G, Shimo Y, Fujimaki M, Kagamihara Y, Shimizu T, Hattori N, Kuwabara S. P856: The effects of motor axonal potassium currents on the disease progression of amyotrophic lateral sclerosis. Clin Neurophysiol 2014. [DOI: 10.1016/s1388-2457(14)50886-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
31
|
Gopinath SCB, Awazu K, Fujimaki M, Shimizu K. Neu5Acα2,6Gal and Neu5Acα2,3Gal receptor specificities on influenza viruses determined by a waveguide-mode sensor. Acta Biomater 2013; 9:5080-7. [PMID: 23022889 DOI: 10.1016/j.actbio.2012.09.027] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2012] [Revised: 08/25/2012] [Accepted: 09/21/2012] [Indexed: 11/20/2022]
Abstract
To characterize the differences in the receptor-binding specificities of human and avian influenza viruses with glycan chains, the authors performed binding analyses using an evanescent field-coupled waveguide-mode biosensor. The experiments were performed on intact viruses and hemagglutinin proteins, using gold-nanoparticle-conjugated Neu5Acα2,6Gal and Neu5Acα2,3Gal glycan chains. Several influenza viruses belonging to subtypes H3N2 (A/Udorn/307/1972, A/Shandong/9/1993, A/Kiev/301/1994, A/Panama/2007/1999, A/Wisconsin/67/2005 and A/Brisbane/10/2007), H1N1 (A/Brisbane/59/2007 and A/California/07/2009) and H5N1 (A/chicken/India/NIV33487/2006) were used. High levels of glycan-based discrimination were observed with the H3N2 strain A/Brisbane/10/2007 due to its specificity with Neu5Acα2,6Gal, but not with Neu5Acα2,3Gal. Possible amino acid residues responsible for the discrimination of human and avian influenza viruses are discussed. These types of sensor-based discriminatory analyses would be very useful for distinguishing between influenza pandemics, especially during the transition and overlapping periods of human and avian influenza viruses with evolutionary changes.
Collapse
Affiliation(s)
- S C B Gopinath
- Electronics and Photonics Research Institute, National Institute of Advanced Industrial Science and Technology-AIST, Central 4, 1-1-1 Higashi, Tsukuba, Ibaraki 305-8565, Japan.
| | | | | | | |
Collapse
|
32
|
Hirano K, Fukae J, Hieda S, Fujimaki M, Ishii H, Tsuboi Y, Kawamura M, Arai H, Hattori N. Eosinophilic meningitis caused by primary angiitis of the central nervous system. Intern Med 2013; 52:1393-6. [PMID: 23774554 DOI: 10.2169/internalmedicine.52.9578] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Eosinophilic meningitis is defined as the presence of 10 eosinophils/mm(3) in the cerebrospinal fluid (CSF) or eosinophils accounting for more than 10% of CSF leukocytes. A 76-year-old man who developed cognitive dysfunction and consciousness disturbance had eosinophilic meningitis (his CSF contained 19.0% eosinophils). Because the etiology was unknown, we performed a brain biopsy. The pathological findings showed inflammatory infiltration in the small-sized arteries of the meninges. The patient was ultimately diagnosed as having primary angiitis of the central nervous system (PACNS). Eosinophilic meningitis occurring in a patient with PACNS is extremely rare, and this is the first report of this condition in Japan.
Collapse
Affiliation(s)
- Kazuoki Hirano
- Department of Neurology, Juntendo University School of Medicine, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Higurashi Y, Ohnishi J, Nakagawa T, Haba H, Tamura M, Aihara T, Fujimaki M, Komiyama M, Uchiyama A, Kamigaito O. Production of a highly charged uranium ion beam with RIKEN superconducting electron cyclotron resonance ion source. Rev Sci Instrum 2012; 83:02A333. [PMID: 22380180 DOI: 10.1063/1.3671743] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
A highly charged uranium (U) ion beam is produced from the RIKEN superconducting electron cyclotron resonance ion source using 18 and 28 GHz microwaves. The sputtering method is used to produce this U ion beam. The beam intensity is strongly dependent on the rod position and sputtering voltage. We observe that the emittance of U(35+) for 28 GHz microwaves is almost the same as that for 18 GHz microwaves. It seems that the beam intensity of U ions produced using 28 GHz microwaves is higher than that produced using 18 GHz microwaves at the same Radio Frequency (RF) power.
Collapse
Affiliation(s)
- Y Higurashi
- RIKEN Nishina Center, 2-1 Hirosawa, Wako-shi, Saitama 351-0198, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Higurashi Y, Ohnishi J, Nakagawa T, Haba H, Tamura M, Aihara T, Fujimaki M, Komiyama M, Uchiyama A, Kamigaito O. Results of RIKEN superconducting electron cyclotron resonance ion source with 28 GHz. Rev Sci Instrum 2012; 83:02A308. [PMID: 22380155 DOI: 10.1063/1.3660821] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
We measured the beam intensity of highly charged heavy ions and x-ray heat load for RIKEN superconducting electron cyclotron resonance ion source with 28 GHz microwaves under the various conditions. The beam intensity of Xe(20+) became maximum at B(min) ∼ 0.65 T, which was ∼65% of the magnetic field strength of electron cyclotron resonance (B(ECR)) for 28 GHz microwaves. We observed that the heat load of x-ray increased with decreasing gas pressure and field gradient at resonance zone. It seems that the beam intensity of highly charged heavy ions with 28 GHz is higher than that with 18 GHz at same RF power.
Collapse
Affiliation(s)
- Y Higurashi
- RIKEN Nishina Center, 2-1 Hirosawa, Wako-shi, Saitama 351-0198, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Nakagawa T, Higurashi Y, Ohnishi J, Aihara T, Tamura M, Uchiyama A, Okuno H, Kusaka K, Kidera M, Ikezawa E, Fujimaki M, Sato Y, Watanabe Y, Komiyama M, Kase M, Goto A, Kamigaito O, Yano Y. First results from the new RIKEN superconducting electron cyclotron resonance ion source (invited). Rev Sci Instrum 2010; 81:02A320. [PMID: 20192341 DOI: 10.1063/1.3259232] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
The next generation heavy ion accelerator facility, such as the RIKEN radio isotope (RI) beam factory, requires an intense beam of high charged heavy ions. In the past decade, performance of the electron cyclotron resonance (ECR) ion sources has been dramatically improved with increasing the magnetic field and rf frequency to enhance the density and confinement time of plasma. Furthermore, the effects of the key parameters (magnetic field configuration, gas pressure, etc.) on the ECR plasma have been revealed. Such basic studies give us how to optimize the ion source structure. Based on these studies and modern superconducting (SC) technology, we successfully constructed the new 28 GHz SC-ECRIS, which has a flexible magnetic field configuration to enlarge the ECR zone and to optimize the field gradient at ECR point. Using it, we investigated the effect of ECR zone size, magnetic field configuration, and biased disk on the beam intensity of the highly charged heavy ions with 18 GHz microwaves. In this article, we present the structure of the ion source and first experimental results with 18 GHz microwave in detail.
Collapse
Affiliation(s)
- T Nakagawa
- Nishina Center for Accelerator Based Science, RIKEN, Hirosawa 2-1, Wako, Saitama 351-0198, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Watanabe R, Munemasa T, Matsumura M, Fujimaki M. Fluorescent liposomes for intravital staining of Kupffer cells to aid in vivo microscopy in rats. ACTA ACUST UNITED AC 2007; 29:321-7. [PMID: 17805433 DOI: 10.1358/mf.2007.29.5.1117556] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
The potential of newly formulated fluorescent-labeled liposomes for the intravital staining of Kupffer cells was evaluated in rats. Fluorescently labeled phosphatidylcholine (PC) was incorporated into liposomes consisting of PC and phosphatidylserine. After intravenous injection, Kupffer cells in the rat liver were intravitally stained and were clearly delineated under the fluorescence image of both confocal laser scanning microscopy and in vivo microscopy. Specificity of the staining was confirmed by immunohistochemistry using the anti-rat macrophage antibody Ki-M2R, which suggested that the liposomes were selectively entrapped by the hepatic reticuloendothelial system. A time-course study revealed that the suitable observation window was between 16 and 24 h after the injection. Phagocytic activity of Kupffer cells after the administration of liposomes was examined by measuring the amount of hepatic uptake of intravenously administered fluorescent microspheres; no detrimental influence of the liposomes on the phagocytic activity was observed. Additionally, no histopathologic changes were found in the livers from liposome-treated rats. Therefore, the fluorescent-labeled liposomes appear to be a useful research tool for labeling Kupffer cells for in vivo microscopic observation of the liver.
Collapse
Affiliation(s)
- R Watanabe
- New Product Research Laboratories II, Daiichi Pharmaceutical Co., Ltd., Edogawa-Ku, Tokyo, Japan.
| | | | | | | |
Collapse
|
37
|
Wang X, Fujimaki M, Awazu K. Photonic crystal structures in titanium dioxide (TiO2) and their optimal design. Opt Express 2005; 13:1486-1497. [PMID: 19495024 DOI: 10.1364/opex.13.001486] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
We propose photonic crystal (PhC) structures in titanium dioxide (TiO2) material which is suitable for micro-nano structure optical device engineering and is a good candidate for visible light application. To provide a guideline for designing TiO2 based PhC, the comprehensive optical band gap maps of both the two-dimensional and three-dimensional structures are computed using the planewave expansion method. For 2D structures, besides the ideal infinite high 2D PhC and conventional air-bridge type slab, we also propose a "sandwich-type" PhC for better robustness and easier fabrication. The optimal thicknesses of both types of PhC slabs are investigated. In 3D PhC, we calculate the Yablonovite structure and its reverse which are made possible recently in our fabrication. For the first time to our knowledge, the computation results indicate that the reversed Yablonovite structure also shows a complete band gap characteristic, although it is smaller compared to that of the normal Yablonovite. The dependence of band gap width on the filling ratio and drilling angles for both types of Yablonovite structures are investigated.
Collapse
|
38
|
Fujimaki Y, Arai N, Nakazawa T, Fujimaki M. Nefiracetam metabolism by human liver microsomes: role of cytochrome P450 3A4 and cytochrome P450 1A2 in 5-hydroxynefiracetam formation. J Pharm Pharmacol 2001; 53:795-804. [PMID: 11428655 DOI: 10.1211/0022357011776144] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
An in-vitro study was conducted to investigate the metabolism of nefiracetam in human liver microsomes and to identify the enzymes responsible for the metabolism. Nefiracetam was hydroxylated by human liver microsomes to 5-hydroxynefiracetam (5-OHN). Eadie-Hofstee plots for the formation of 5-OHN suggested substrate activation. The kinetic parameters, apparent Km, Vmax, and Hill coefficient, for the formation of 5-OHN by pooled human liver microsomes were 4012 microM, 2.66 nmol min(-1) (mg protein)(-1), and 1.65, respectively. The formation of 5-OHN was significantly correlated with cytochrome P450 (CYP)3A4-mediated testosterone 6beta-hydroxylase activity and dextromethorphan N-demethylase activity. The 5-OHN formation was inhibited (94%) by antibody to human CYP3A4/5. The 5-OHN formation was also inhibited by the CYP3A4 inhibitors ketoconazole and troleandomycin, but not significantly inhibited by several other P450 inhibitors. The microsomes containing cDNA-expressed CYP3A4 formed 5-OHN with sigmoidal kinetics. CYP3A5-containing microsomes did not form 5-OHN. These results indicated that CYP3A, most likely CYP3A4, was the major isozyme responsible for the formation of 5-OHN in human liver microsomes. CYP1A2 and CYP2C19 microsomes were also capable of forming 5-OHN. However, the contribution of CYP1A2 was considered to be relatively minor compared with that of CYP3A4, and the contribution of CYP2C19 was assumed to be negligible, based on the result of the immunoinhibition study and taking into account both the turnover rate by each isozyme and the relative abundance of each isozyme in human liver. We conclude that on average the formation of 5-OHN, the major metabolite of nefiracetam, is principally mediated by CYP3A4 with a relatively minor contribution by CYP1A2.
Collapse
Affiliation(s)
- Y Fujimaki
- Drug Metabolism and Analytical Chemistry Research Laboratory, Daiichi Pharmaceutical Co., Ltd., Tokyo, Japan
| | | | | | | |
Collapse
|
39
|
Hitosugi N, Ohno R, Hatsukari I, Mizukami S, Nagasaka H, Matsumoto I, Komatsu N, Fujimaki M, Nakashima H, Satoh K, Sakagami H. Diverse biological activities of moxa extract and smoke. In Vivo 2001; 15:249-54. [PMID: 11491021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
Abstract
Diverse biological activities of moxa extracts and smoke (gas phase) were investigated. Moxa was extracted with hot water (Fr. I), or ethanol (Fr. II), or extracted with hot water after ethanol wash (Fr. III) and then lyophilized to obtain the dried powders. Moxa smoke (containing a lot of gaseous components obtained by burning Moxa) (Fr. IV) was collected into phosphate-buffered saline and quantified spectrophotometrically. These extracts and Moxa smoke showed comparable cytotoxic activity against human oral tumor cell lines (HSC-2, HSG). Human gingival fibroblasts (HGF) were more resistant to any Moxa fractions. Neither of the extracts showed anti-HIV activity. Pretreatment of mice with Fr. I significantly reduced the lethal effect of E. coli infection. All extracts produced radicals under alkaline condition, with a maximum intensity at pH 10.5, and enhanced the radical intensity of sodium ascorbate. It was unexpected that these extracts show significant O2- scavenging activities. These data suggest the medicinal efficacy of Moxa extracts and smoke.
Collapse
Affiliation(s)
- N Hitosugi
- Department of Anesthesia, Saitama Medical School, Saitama, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Jiang Y, Satoh K, Aratsu C, Komatsu N, Fujimaki M, Nakashima H, Kanamoto T, Sakagami H. Diverse biological activity of polycaphenol. In Vivo 2001; 15:145-9. [PMID: 11317519] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Abstract
Millimolar concentrations of alkaline extract of Cacao husk (polycaphenol) were more cytotoxic to human oral tumor cells (human oral squamous cell carcinoma HSC-2, human salivary gland tumor HSG), than to human gingival fibroblast (HGF), suggesting its tumor-specific action. Polycaphenol enhanced the radical intensity and cytotoxic activity of vitamin K3 more effectively than that of sodium ascorbate (vitamin C). Polycaphenol effectively scavenged the superoxide anion, produced by the hypoxanthine-xanthine oxidase reaction, indicating bimodal (prooxidant and antioxidant) action of polycaphenol. Polycaphenol inhibited the cytopathic effect of HIV (human immunodeficiency virus) infection in MT-4 cells, to a comparable extent as that achieved by lignin. Pretreatment of mice with polycaphenol protected them from lethal infection of Eschericia coli. These data suggest the medicinal efficacy of polycaphenol.
Collapse
Affiliation(s)
- Y Jiang
- Meikai Pharmaco-Medical Laboratory (MPL), Meikai University School of Dentistry, Sakado, Saitama, Japan
| | | | | | | | | | | | | | | |
Collapse
|
41
|
Saito M, Sakamoto T, Fujimaki M, Tsukada K, Honda T, Nozaki M. Experimental study of an artificial esophagus using a collagen sponge, a latissimus dorsi muscle flap, and split-thickness skin. Surg Today 2001; 30:606-13. [PMID: 10930226 DOI: 10.1007/s005950070100] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
The time and effort spent trying to devise an artificial esophagus have not yet resulted in success, and leakage and strictures at the anastomotic sites remain the most frequent complications. We developed an artificial esophagus with a bilayered structure made of porous collagen sponge (artificial dermis; AD), a latissimus dorsi muscle flap (LD), and split-thickness skin (STS). We investigated whether the use of AD prevented the contraction of grafted skin and its effects on the extensibility of the neoesophagus in rabbits. We experimented with two groups. In the AD group, AD was applied to the surface of the LD. Three weeks later, the STS was grafted. In the control group, the STS was grafted directly onto the LD. The sizes of the STS in both groups 3 weeks after the graft were, respectively, 56.6% +/- 4.1% and 39.0% +/- 10.2% of the initial surface area of the STS (P < 0.01). The roll made in the AD group had better extensibility than that in the control group. We replaced the cervical esophagus in 12 rabbits with the neoesophagus made from AD, STS, and LD. The longest survival period was 16 days. Esophagography did not reveal either anastomotic leakage or stenosis in any of the five rabbits in the experiments. These findings suggested that AD can thus be used to create a more suitable hybrid artificial esophagus.
Collapse
Affiliation(s)
- M Saito
- Second Department of Surgery, Toyama Medical and Pharmaceutical University, Japan
| | | | | | | | | | | |
Collapse
|
42
|
Kobayashi N, Unten S, Kakuta H, Komatsu N, Fujimaki M, Satoh K, Aratsu C, Nakashima H, Kikuchi H, Ochiai K, Sakagami H. Diverse biological activities of healthy foods. In Vivo 2001; 15:17-23. [PMID: 11286123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Abstract
Diverse biological activities of 7 healthy foods [powdered pine needle, citrate-fermented sesame, powdered coffee, royal jelly, propolis, pollen and white sesame oil (extracted by super critical state (40 degrees C, 350 atmospheric pressure))] were investigated. The pine needle, sesame and powdered coffee was also extracted successively by ethanol and hot water, and lyophilized. The pine needle and coffee extracts, and propolis showed higher in vitro cytotoxic, bactericidal and oxidation activity, as compared with other 4 lipophilic healthy foods. However, propolis showed slightly lower, but significant cytotoxic and bactericidal activity with much reduced oxidation potential. ESR spectroscopy demonstrated that the cytotoxic activity of these extracts was closely related to their radical generation and O2- scavenging activities. Healthy food components may have both pro-oxidant and anti-oxidant properties. Pre-treatment of mice with pine needle, sesame or powdered coffee extract significantly reduced the lethality of bacterial infection, possibly due to their host-mediated action. These extracts failed to reduce the cytophatic effect of HIV-1 (human immunodeficiency virus) infection in MT-4 cells. No apparent acute toxicity was detected in mice by oral administration of 10 g/kg of these extracts. This data suggest the medicinal efficacy of healthy foods.
Collapse
|
43
|
Satoh K, Sakagami H, Ida Y, Komatsu N, Fujimaki M, Nakashima H, Kanbara K, Gupta M, Sarma DN, Mitra SK. Antimicrobial and radical modulation activity of AV-07, a poly-herbal formula. In Vivo 2000; 14:351-5. [PMID: 10836209] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Abstract
An extract of AV-07 was investigated for various biological activities. Pretreatment of mice with the AV-07 extract significantly protected them from lethal infection with E. coli. ESR spectroscopy showed that the extract produced radicals under alkaline conditions and enhanced the radical intensity of sodium ascorbate, suggesting its pro-oxidant action at higher concentrations. The extract effectively scavenged superoxide anion, produced by hypoxanthine-xanthine oxidase reaction and hydroxyl radical, produced by Fenton reaction. These data demonstrate that AV-07 extract contains various bioactive substances, suggesting its medicinal efficacy.
Collapse
Affiliation(s)
- K Satoh
- Analysis Center, School of Pharmaceutical Sciences, Showa University, Shinagawa-ku, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Fujimaki M, Ohki Y, Brebner JL, Roorda S. Fabrication of long-period optical fiber gratings by use of ion implantation. Opt Lett 2000; 25:88-89. [PMID: 18059791 DOI: 10.1364/ol.25.000088] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
We report the fabrication of long-period optical fiber gratings by use of a refractive-index increase induced by ion implantation. Helium ions were implanted in an optical fiber core through a metal mask that had a 170-microm -pitch grating with spacing of 60 microm . We obtained a wavelength-dependent effective transmission loss by use of the grating.
Collapse
|
45
|
Tazawa K, Shimoda M, Nagata T, Sasahara K, Bando T, Ansai Y, Shimizu T, Arai H, Sakamoto T, Fujimaki M, Tsukada K, Tazawa K. Splenic artery aneurysm associated with systemic lupus erythematosus: report of a case. Surg Today 1999; 29:76-9. [PMID: 9934837 DOI: 10.1007/bf02482975] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
We herein report on a 64-year-old Japanese female patient who presented with a splenic artery aneurysm (SAA) associated with systemic lupus erythematosus (SLE). The saccular aneurysm, which measured 3 cm in diameter, was located in the proximal third of the splenic artery from the pancreas with a portosystemic shunt. A double ligation of the splenic artery (the distal and proximal sides of the aneurysm) was performed without a splenectomy. The postoperative course showed acute pancreatitis without either splenic infarction or portal thrombus. To our knowledge, the closed association of SLE with an aneurysmal dilatation of the splenic artery has not been previously reported. Both the pathogenesis and the management of SAA associated with SLE are discussed following the presentation of this case. This is the first reported case of SAA associated with SLE.
Collapse
Affiliation(s)
- K Tazawa
- Second Department of Surgery, Faculty of Medicine, Toyama Medical and Pharmaceutical University, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Satoh K, Kihara T, Ida Y, Sakagami H, Koyama N, Premanathan M, Arakaki R, Nakashima H, Komatsu N, Fujimaki M, Misawa Y, Hata N. Radical modulation activity of pine cone extracts of Pinus elliottii var. Elliottii. Anticancer Res 1999; 19:357-64. [PMID: 10226567] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
Abstract
The radical modulation activity of lignins prepared from the cone of Pinus elliottii var. Elliottii was investigated, using ESR spectroscopy. These lignins produced radical(s) under alkaline conditions, and the radical intensity was increased with increasing pH. Lower concentrations of lignins slightly reduced the radical intensity of sodium ascorbate, whereas higher concentrations of lignins enhanced both the radical intensity and cytotoxic activity of sodium ascorbate. Lignins effectively scavenged superoxide anion, produced by hypoxanthine-xanthine oxidase reaction. Elliottii lignins significantly inhibited the human immunodeficiency virus (HIV)-induced cytopathic effect, in similar fashions to other natural, commercial and synthetic lignins. Pretreatment of mice with lignins significantly protected them from the lethal infection with E. coli. Crude alkaline extracts of Elliottii pine cone displayed similar magnitude of activity with lignins. These data further supports the medicinal efficacy of plant extracts.
Collapse
Affiliation(s)
- K Satoh
- Analysis Center, School of Pharmaceutical Sciences, Showa University, Tokyo, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Sakagami H, Kashimata M, Toguchi M, Satoh K, Odanaka Y, Ida Y, Premanathan M, Arakaki R, Kathiresan K, Nakashima H, Komatsu N, Fujimaki M, Yoshihara M. Radical modulation activity of lignins from a mangrove plant, Ceriops decandra (Griff.) Ding Hou. In Vivo 1998; 12:327-32. [PMID: 9706479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
The radical modulation activity of hot water and alkaline extracts from leaf of Ceriops decandra, a mangrove plant, was investigated using ESR spectroscopy. IR and NMR analyses demonstrate that the leaf extracts have a lignin-like polyphenolic structure. All these extracts produced radical(s) under alkaline conditions. The radical intensity of sodium ascorbate was slightly reduced at lower concentrations of the extracts, but it was synergistically enhanced at higher concentrations. All the extracts effectively scavenged superoxide anion, produced by hypoxanthine-xanthine oxidase reaction. Pretreatment of mice with the extracts significantly protected them from the lethal infection by E. coli. Similar activity was found in lignins from pine seed shell of Pinus parviflora Sieb. et Zucc. These data further support the medicinal efficacy of plant extracts.
Collapse
Affiliation(s)
- H Sakagami
- Department of Dental Pharmacology, Meikai University School of Dentistry, Saitama, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Hirokawa S, Yamashita I, Kuroki Y, Yamashita Y, Fujimaki M, Aoyama K, Murakami J. Neuroblastoma in an adult with a high serum level of carbohydrate antigen, CA125: report of a case. Surg Today 1998; 28:349-54. [PMID: 9548327 DOI: 10.1007/s005950050139] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
We report herein the case of a 56-year-old woman with a neuroblastoma associated with a high serum level of carbohydrate antigen, CA125. The patient presented with massive ascites and a firm mass in her upper abdomen for which a laparotomy was performed. However, a recurrent tumor was found 6 months later and she died of the disease within 1 year of surgery despite several courses of adjuvant chemotherapy. Neuroblastoma rarely occurs in adults, and the features of 58 adult cases described in the world literature is summarized following the presentation of the clinical data on this case. The distribution of primary sites in adults is dispersed compared to that seen in pediatric cases, while the natural history of the disease in adults may be longer and less sensitive to chemotherapy than in children. The survival rate of adults with this disease is poor. We conclude that aggressive surgical intervention combined with appropriate chemotherapy protocols as applied in children should be performed in an attempt to achieve complete remission and improve the survival rate of adults with neuroblastoma.
Collapse
Affiliation(s)
- S Hirokawa
- Department of Surgery, Asahi General Hospital, Toyama, Japan
| | | | | | | | | | | | | |
Collapse
|
49
|
Ohnishi Y, Fujii H, Murakami K, Sakamoto T, Tsukada K, Fujimaki M, Kojima M, Saiki I. A new pseudo-peptide analogue of the Arg-Gly-Asp (RGD) sequence inhibits liver metastasis of colon 26-L5 carcinoma cells. Cancer Lett 1998; 124:157-63. [PMID: 9500205 DOI: 10.1016/s0304-3835(97)00473-4] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
We have investigated the effect of the pseudo-peptide analogue (FC-336) of the Arg-Gly-Asp (RGD) sequence in a liver metastasis model by the inoculation of a highly liver-metastatic cell line of colon 26 carcinoma (colon 26-L5) into the portal vein of BALB/c mice. The intraportal injection of colon 26-L5 cells with FC-336 resulted in a marked suppression of liver metastatic colonies in a dose-dependent manner and it reduced the liver weights to a normal level. However, the co-injection of tumor cells with a high dose of RGDS tetrapeptide led to a slight inhibition of liver metastasis. The multiple i.v. administration of FC-336 after tumor inoculation as well as the injection of FC-336 with tumor cells caused significant inhibition of experimental metastasis in the liver. The multiple i.v. administration of the RGDS peptide did not show any inhibitory activity. FC-336 significantly enhanced the survival rate of mice compared with untreated controls when injected intraportally with tumor cells or when intravenously administered after tumor inoculation. Zymography analysis showed that FC-336 inhibited the degradation of gelatin substrate by matrix metalloproteinases (MMPs) produced by colon 26-L5 cells, while RGDS peptide did not affect the enzymatic degradation. These findings clearly indicate that the pseudo-peptides of the RGD sequence (FC-336) have a potent inhibitory activity on liver metastasis of colon 26-L5 carcinoma cells.
Collapse
Affiliation(s)
- Y Ohnishi
- Department of Pathogenic Biochemistry, Research Institute for Wakan-yaku, Toyama Medical and Pharmaceutical University, Sugitani, Japan
| | | | | | | | | | | | | | | |
Collapse
|
50
|
Ohnishi Y, Fujii H, Hayakawa Y, Sakukawa R, Yamaura T, Sakamoto T, Tsukada K, Fujimaki M, Nunome S, Komatsu Y, Saiki I. Oral administration of a Kampo (Japanese herbal) medicine Juzen-taiho-to inhibits liver metastasis of colon 26-L5 carcinoma cells. Jpn J Cancer Res 1998; 89:206-13. [PMID: 9548449 PMCID: PMC5921762 DOI: 10.1111/j.1349-7006.1998.tb00550.x] [Citation(s) in RCA: 60] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
We have investigated the inhibitory effect of oral administration of Juzen-taiho-to, a Kampo Japanese herbal medicine, on liver metastasis by the inoculation of a liver-metastatic variant (L5) of murine colon 26 carcinoma cells into the portal vein. Oral administration of Juzen-taiho-to for 7 days before tumor inoculation resulted in dose-dependent inhibition of liver tumor colonies and significant enhancement of survival rate as compared with the untreated control, without side effects. We also found that liver metastasis of L5 cells was enhanced in BALB/c mice pretreated with anti-asialo GM1 serum or 2-chloroadenosine, and in BALB/c nu/nu mice, compared to normal mice. This indicates that NK cells, macrophages, and T-cells play important roles in the prevention of metastasis of tumor cells. Juzen-taiho-to significantly inhibited the experimental liver metastasis of colon 26-L5 cells in mice pretreated with anti-asialo GM1 serum and untreated normal mice, whereas it did not inhibit metastasis in 2-chloroadenosine-pretreated mice or T-cell-deficient nude mice. Oral administration of Juzen-taiho-to activated peritoneal exudate macrophages (PEM) to become cytostatic against the tumor cells. These results show that oral administration of Juzen-taiho-to inhibited liver metastasis of colon 26-L5 cells, possibly through a mechanism mediated by the activation of macrophages and/or T-cells in the host immune system. Thus, Juzen-taiho-to may be efficacious for the prevention of cancer metastasis.
Collapse
MESH Headings
- 2-Chloroadenosine/pharmacology
- Administration, Oral
- Animals
- Anticarcinogenic Agents/therapeutic use
- Antineoplastic Agents, Phytogenic/therapeutic use
- Colonic Neoplasms/drug therapy
- Colonic Neoplasms/pathology
- Cytotoxicity, Immunologic/drug effects
- Drug Interactions
- Drugs, Chinese Herbal/therapeutic use
- Female
- G(M1) Ganglioside/immunology
- Immune Sera/pharmacology
- Killer Cells, Natural/drug effects
- Killer Cells, Natural/immunology
- Liver Neoplasms, Experimental/prevention & control
- Liver Neoplasms, Experimental/secondary
- Macrophages, Peritoneal/drug effects
- Macrophages, Peritoneal/immunology
- Male
- Mice
- Mice, Inbred BALB C
- Mice, Nude
- Neoplasm Transplantation
- Stimulation, Chemical
Collapse
Affiliation(s)
- Y Ohnishi
- Department of Pathogenic Biochemistry, Research Institute for Wakan-yaku, Sugitani, Toyama
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|